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ABSTRACT 
Diabetes is one of the major health problems of the 21st century. Dysfunction of the insulin 
secreting pancreatic β-cell together with insulin resistance is central to the pathogenesis of 
type 2 diabetes mellitus (T2DM). The cause of the disease and the underlying mechanisms 
linking hyperglycemia to diabetes complications are still unclear. This thesis is focused on 
two cellular organelles, the mitochondrion and the primary cilium, and their role in the 
pathophysiological mechanisms of diabetes and its complications.  
In the first paper, we studied the effect of hyperglycemia on cell biology and energy 
metabolism in human primary fibroblasts and endothelial cells. Acute hyperglycemia 
triggered a metabolic switch from mitochondrial respiration to aerobic glycolysis, which was 
persistent after prolonged exposure together with reduced ATP/ADP ratio without increase in 
reactive oxygen species (ROS). An acute decrease in mitochondrial transmembrane potential 
and cellular proliferation with changes in cytoskeletal reorganization was linked to the 
increased osmotic pressure induced by hyperglycemia. 
In the second and third papers we investigated the effect of hypoxia, a common feature in 
diabetes, and hyperoxia in pancreatic islets. Here, we found deleterious effects on 
mitochondrial content, respiration and glucose-stimulated insulin secretion. Preconditioning 
with the K+ATP channel opener diazoxide enhanced insulin release, HIF-1α and AMPK 
activation and improved β-cell survival in response to hypoxia.  
In the fourth paper, a role for the β-cell primary cilium in diabetes was reported. We found 
reduced first phase insulin secretion in ciliary defective cells and islets, and impaired glucose 
tolerance in a ciliopathy mouse model. These results were linked to impaired recruitment of 
insulin receptor A to the cilium, necessary for proper insulin signaling. Mitochondrial 
respiration and glucose uptake was unaffected by cilia impairment. Additionally, in vivo 
evidence of ciliary morphology alteration in the GK rat, a model of T2DM, supported a 
relationship between ciliary defect and T2DM.  
Preliminary results show that decreasing intracellular ATP and increasing mitochondrial ROS 
production impaired cilia morphology and/or number in two different cell types. Further, cilia 
were decreased in number with altered morphology in the kidneys of a mouse model of 
T2DM with diabetic nephropathy, characterized by increased ROS and altered mitochondrial 
metabolism.  
Finally, a reduction of 60-80% in mtDNA content (reported in diabetes) did not affect 
mitochondrial metabolism, respiration and energy production in two different cell types. 
In summary, mitochondrial dysfunctions during diabetes and its complications are most 
probably due to a combination of hyperglycemia and other factors such as hypoxia, 
depending on the cells and tissues involved. A proper ciliary/basal body function is necessary 
for insulin release and signaling in β-cell. Cilia morphology and number can be affected by 
mitochondrial dysfunction/ROS and thus related to diabetic complications such as diabetic 
nephropathy.  
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1 INTRODUCTION 
1.1 DIABETES 
1.1.1 Epidemiology of Diabetes 
Diabetes mellitus (DM) is defined as a group of genetic, metabolic or acquired conditions that 
manifest with hyperglycemia. The growing diabetic epidemics affect around 347 million 
people worldwide and can be linked to increased food intake, overweight and sedentary 
lifestyle. In 2012 diabetes was the direct cause of 12 million deaths (fourth leading cause in 
Europe (1)) and this figure is predicted to rise by 50% in the coming 10 years. The majority 
(80%) of death takes place in countries with low or middle income and is mainly due (50-
80%) to the cardiovascular complications of diabetes (2). Moreover, chronic diabetes 
complications are major health issues, especially in those countries with insufficient 
healthcare to provide awareness and pharmacological aid. In fully developed countries, these 
complications are better contained but nevertheless diabetes is an extreme economic burden 
on society. In Sweden the diabetes healthcare uses 8% of the total resources (3). Of special 
concern is the emerging of adolescent type 2 diabetes mellitus (T2DM) (4), which is 
associated to the increase in children obesity. 
1.1.2 Classification and Diagnosis 
Until 2009, the diagnosis of diabetes was based only on plasma measurements of glucose. 
The cut off levels included fasting glucose >7mM (126mg/dl) or >11mM (200mg/dl) 2h after 
oral glucose tolerance test (OGTT), or the same concentration in patients with symptoms of 
hyperglycemia. From 2009, an international committee of experts recommended to add the 
value of glycosylated hemoglobin (HbA1c) >6.5% (>48 mmol/mol) as diagnosis of diabetes. 
The advantages are the absence of fasting procedures and the readout of 2-3 months of 
glycemic history prior the measurement (red blood cells lifespan). However, the cut-off at 
6.5% identifies one-third less cases of diabetes than plasma fasting glucose (5). 
Depending on the pathogenesis, diabetes mellitus can be classified in: 
- Type 1 Diabetes (T1DM), which includes approximately 5-10% of the total 
number of subjects with diabetes. It is the most common type of diabetes in children or young 
adults but yearly incidence is more common in adults. The exact cause is not known, 
however, in most cases an autoimmune reaction is responsible for the destruction of β-cells in 
the islets of Langerhans leading to insulin deficiency and the need of insulin treatment to 
survive. 
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- Type 2 Diabetes (T2DM), which represents the majority of cases (around 90%) 
of diabetes. It is the result of a progressive defect in insulin secretion and insulin resistance. 
- Gestational Diabetes (GDM) occurs between the 24th-28th weeks of pregnancy 
and affect around 4-7% of the pregnant women in the United States. It is a form of T2DM, 
which in most cases disappear after delivery. When present, GDM increases the risk of later 
T2DM onset. 
- Other diabetes types dependent on specific causes (genetic defects, pancreatic 
diseases, tumors and drug or chemically induced diabetes).  
In many cases, especially regarding T2DM, the metabolic derangements that culminate with 
the manifestation of the disease are recognized before the diagnosis. In fact, a category of 
people whose glucose levels are too high to be considered normal, although not meeting the 
criteria for diagnosis of diabetes, is classified as prediabetic subjects. Prediabetes is defined 
with impaired fasting glucose (IFG) with levels ranging between 5.6 and 6.9 mM (100 to 125 
mg/dl) or impaired glucose tolerance (IGT) during OGTT 7.8-11mM (140-199 mg/dl). 
Subjects with IFG and IGT are at high risk to develop diabetes and cardiovascular disease 
and have often comorbidity with obesity, dyslipidemia and hypertension (5). 
1.1.3 Hormone Biology 
Glucose homeostasis is regulated by a crosstalk between pancreatic and gut hormones. In a 
normal adult, the available glucose stores can meet the energy demands for 12-18 hours, 
while triglycerides stores are considered 100 times larger. In the pancreas, the endocrine 
portion is responsible for producing hormones, while the exocrine part is secreting enzymes 
for digestions of macronutrient derived from the diet. The pancreatic Islets of Langerhans are 
the functional units producing hormones and consist of α, β, δ, pp or γ and ε cells. The β-cells 
are the majority of the islet cells and secrete insulin, the hormone responsible for metabolism 
and fuel storage. The ingestion of carbohydrates is capable to induce half of the postprandial 
insulin release, while another half is facilitated by gut hormones such as glucagon-like 
peptide-1 (GLP1) secreted by L cells in the intestine, and in small proportions gastric 
inhibitory peptide (GIP), secreted by K cells in the proximal intestine, which actions are to 
slow down gastric emptying, decrease glucagon release and reduce food intake (6, 7). The α-
cells are responsible for producing the insulin-counteracting hormone glucagon. Its action 
during hypoglycemia is to promote glucose release from the liver (gluconeogenesis), and to 
mobilize fatty acids. The balance between insulin and glucagon determinates glucose 
homeostasis, fatty acid metabolism and protein preservation. Δ-cells are responsible for 
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secretion of somatostatin, a hormone acting on both α and β cells regulating their secretion. 
PP or γ-cells are responsible for producing pancreatic polypeptide, which regulates both 
exocrine and endocrine secretions, and the ε-cells for secretion of ghrelin, a protein that 
stimulates hunger.  
The insulin secretion process begins with the entry of glucose in the β-cells mediated by 
GLUT2 and its phosphorylation by the enzyme glucokinase. Thus, the glycolysis is enhanced 
and increases the pyruvate concentration that, in this cell type, cannot be converted to lactate 
due to the lack of monocarboxylate transporter (8). Due to the low ATP/ADP ratio in resting 
β-cells, the pyruvate is rapidly metabolized in the mitochondria with increased electron flux 
and membrane potential. This increases the level of cellular ATP, which closes the ATP-
sensitive K+ channels. The cell then depolarizes resulting in Ca2+ influx through the voltage-
gated Ca2+ channels. This raise of intracellular Ca2+ mediates insulin exocytosis. In this 
process the mitochondria is one of the key components being both responsible for the 
production of ATP and indirectly inducing synthesis of amplification factors such as cAMP, 
GTP, long-chain Acyl-CoA, NADPH and glutamate, that stimulate insulin exocytosis (9). 
During diabetes condition, the metabolism of liver, muscle and adipose tissue recalls the 
fasting state. In fact, the low levels of insulin (in T1DM and late T2DM) and the presence of 
glucagon in the blood raise the level of fatty acids and ketone bodies that are used as fuel by 
several tissues, while the liver produces glucose to meet the expectations of the brain and 
other organs which uses it as preferential substrate. However, the low levels of insulin 
decrease the glucose uptake by muscle and adipose tissues due to the inability to expose their 
main glucose transporter (GLUT4) to the plasma membrane. Moreover, the presence of 
glucagon in the blood drives muscle and adipose tissues to release fatty acids and 
gluconeogenic ammino acids. 
Non-insulin dependent cells and tissues (for example vessels and nerves among others) 
respond in a total different manner not being dependent on the GLUT4 exposure for glucose 
uptake. Accumulation of glucose, which can pass via the GLUT1 transporter, causes damage 
in these cells probably involving the mechanisms discussed below (see 1.1.5). 
1.1.4 Diabetes Complications 
Complications of diabetes can be divided in two major categories: acute and chronic or long-
term complications. The acute complications are associated with high mortality and are 
caused by ketoacidosis, dehydration, respiratory infections, seizures or coma, which occur 
under extreme conditions of hypoinsulinemia and hypoglycemia or hyperglycemia. The 
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chronic complications, such as nephropathy, neuropathy, cardiovascular events and 
retinopathy affect tissues not dependent on insulin receptors or GLUT4 for glucose entry and 
are associated with high medical costs and low life-quality of diabetic patients. Here, due to 
the possible role of mitochondria and primary cilia in their pathophysiological mechanisms, 
we focused on the chronic complications of diabetes. 
1.1.4.1 Nephropathy 
Diabetic nephropathy develops in 30-40% of patients with T1DM or T2DM and is the 
strongest predictor of mortality in diabetes (10). The risk of chronic kidney disease is 11 fold 
increased in T1DM and 3 times in T2DM and raises the risk of cardiovascular disease (11). 
Even though diabetic nephropathy develops years after the first signs of diabetes, kidney 
hypertrophy and elevated volume of glomerular filtration increase early after the disease 
onset (12). Tight glycemic control reduces the onset and progression of diabetic nephropathy 
in T1DM and in lesser extent in T2DM, suggesting different mechanisms of disease 
progression. Proximal tubular cells and podocytes seem to be the cells affected first in the 
process. Some of them undergo apoptosis, while the others change shape and size, 
reorganizing their cytoskeleton to cover the basement membrane (10). 
1.1.4.2 Retinopathy 
Diabetic retinopathy is the major cause of blindness in working-age adults. In T1DM the 
majority of cases are presented as proliferative retinopathy while in T2DM as macula edema, 
which is a breakdown of blood-retinal barrier and leakage of plasma in the macula (13). If 
followed for 20 years, almost all T1DM patients and 80% of T2DM develop retinopathy (14). 
50% of T1DM patients but only 10% of T2DM develop proliferative retinopathy. This 
number becomes higher in T2DM patients with severe impairment of insulin secretion. 
Previously classified as microvascular complication, in recent years neuroretinal degeneration 
has been found to precede the vascular lesions. Since the retina is a complex organ composed 
of several cell types interconnected by metabolic and signaling pathways (neurons, retinal 
pigmented, pericytes, astrocytes, Müller, endothelial and glial cells), it is not yet known 
which type is involved first in the process (15). Early studies pinpointed hyperglycemia as the 
trigger of diabetic retinopathy leading to selective degeneration of pericytes and subsequent 
apoptosis of endothelial cells (16, 17). Moreover, clinical studies report a strong association 
between increased HbA1c and retinopathy (18, 19). However, recent hypothesis indicate that 
insulin deficiency is a separate risk factor. In fact, the retina as a whole is now thought to be 
an insulin sensitive tissue and that hyperglycemia can impair the insulin signaling as in the 
peripheral tissues (15).   
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1.1.4.3 Neuropathy 
More than half of all diabetic patients will develop neuropathy (20). This is a syndrome that 
causes demyelination originating from Schwann cells, axonal degeneration and involves the 
endothelium in close relationship with the neurons (metabolic and ischemic roles). Moreover, 
an inflammatory process is likely to be involved in the development and progression of this 
complication, especially in T2DM (21). Diabetic neuropathy does not affect only sensory 
neurons but also the autonomic nerves resulting in cardiovascular disturbances, gastroparesis, 
diarrhea, bladder atony and impotence. The classical sensory polyneuropathy affects first 
long sensory distal neuronal fibers and slowly progresses to the proximal ones. This 
complication can be totally silent and it can be discovered only by chance (foot care) or 
because of pain. Not all patients develop neuropathy indicating a genetic predisposition such 
as polymorphism of aldose reductase activity (22). The focal or multifocal neuropathy is seen 
more frequently in T2DM after 50 years of age and includes oculomotor nerve palsies, 
truncal neuropathy, muscle weakness and atrophy (21). Patients with IGT display a milder 
form of neuropathy that is restricted to small fibers compared to diabetic patients showing 
that its severity correlates with glucose dysregulation or hyperglycemic spikes (23). 
1.1.4.4 Cardiovascular Complications 
Cardiovascular disease (CVD) is the major cause of death in diabetes. In fact, T1DM and 
T2DM increase the occurrence of myocardial infarction 10 fold and 5 fold respectively. This 
risk is cumulative with the metabolic syndrome. Diabetes is also correlated to an increased 
risk of stroke, which can be predicted by the glucose history levels (24). Moreover, peripheral 
artery disease during diabetes causes occlusions and pain especially in the lower extremities, 
and increases the risk of limb amputation.  
1.1.5 Mitochondria and Metabolism as Trigger for Diabetes Complications 
The pathogenesis of the chronic complications of diabetes is still matter of debate and 
intensive studies in order to find valid therapeutic approaches to stop or delay their 
progression (25). The most prominent chronic diabetes complications are retinopathy in 
T1DM and CVD in T2DM followed by neuropathy and nephropathy.  
It is commonly thought that the complications of diabetes arise mainly, but not only, due to 
the high blood glucose and its accumulation in the cells. However, some cells or tissues might 
adjust to, or escape from gluco-toxicity, while others might be affected. The primary 
difference between cell adaptation and crisis might be the expression of different glucose 
transporters (GLUT). Nearly all tissues express GLUT1, including human β-cells, with 
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highest concentration in blood and endothelial cells, astrocytes and cardiac muscle (26). It 
facilitates the diffusion of glucose across the plasma membrane rapidly equilibrating the 
sugar concentration between the two sides. The regulation of GLUT1 can be transcriptional 
and post-transcriptional. Glucose deprivation and hypoxia increase the transcription and 
stability of GLUT1, while hyperglycemia has no effect (27). In contrast, high glucose causes 
capillary hypoxia (28, 29) and inhibits stabilization of hypoxic inducible factor HIF-1α 
interfering with the adaptation to hypoxia (30). These conditions can explain some of the 
diabetes related complications. Pancreatic β-cells in rodents and epatocytes express mainly 
GLUT2, which has an extremely high Km for glucose. Other insulin sensitive tissues 
involved in storage (fat) and utilization (muscle) of glucose, express mainly GLUT4, which is 
transported from the cytosol to the plasma membrane in response to insulin.   
The high glucose concentration in the blood and its consequent accumulation in the cells has 
been postulated to be responsible for the development of the diabetic complications via the 
mitochondria (31). In fact, Brownlee and colleagues suggested that an increase of 
mitochondrial metabolism derived from the pyruvate delivery into the mitochondria and 
subsequent raise of mitochondrial membrane potential (Δψm) induces an overproduction of 
superoxide anion. The excess of reactive oxygen species (ROS) that escape mitochondria 
might inhibit directly the enzyme GAPDH or activating the DNA repair enzyme poly (ADP-
ribose) polymerase (PARP). As consequence of the inhibition of GAPDH by ROS and 
possibly PARP, glycolytic substrates accumulate within cells and feed the pathways 
upregulated during diabetes complications (32, 33). Although very intriguing, this hypothesis 
might be dependent on the metabolic state and demand of the cells involved.  
An alternative previous theory suggested that changes in pyridine nucleotide balance 
(especially a reduction in NAD+/NADH ratio), due to the intracellular accumulation of 
glucose in permissive cells, is the cause of development and progression of diabetic 
complications. Williamson and colleagues called this imbalance “pseudohypoxia” because of 
the similar metabolic characteristics found in response to hypoxia but in presence of normal 
oxygen tension (34). Excess of glucose entrance into the pentose phosphate and sorbitol 
pathways, as well as enhanced glycolysis, can increase the NADH and/or NADPH levels in 
the cells (35). The possibility of re-oxidation might be inhibited in the mitochondria when an 
excess of substrates or high ATP levels are present and the NADH has to be oxidized via 
production of lactate. In fact, an increase of NADH/NAD+ is reflected by an increase of the 
lactate/pyruvate ratio. A small imbalance of pyridine nucleotides can affect several enzymes 
and pathways such as increase of diacylglycerol synthesis, inhibition of fatty acid oxidation 
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and prostaglandin production. Further measurements of the redox state of pyridine 
nucleotides in cytosol and mitochondria of different cell types and tissues using innovative 
methods would further clarify this mechanism of action described by the authors (36-38).  
Although these two theories have gathered much attention as potential explanation for the 
complications of diabetes, the mechanism behind these complications may be different in 
different tissues and is still a matter of debate and intense research. The challenge is to 
develop tools and characterize metabolic changes in vivo in the affected tissue, for example 
monitoring substrate oxidation, ROS production, pyridine nucleotide balance and ATP to 
understand which the primary impairment is and how to intervene.  
1.1.6 Therapies 
The introduction of recombinant insulin, improved methods to monitor glucose and pump 
systems to infuse insulin, strongly reduced the risk of hypoglycemia and extended the life 
expectancy of patients with T1DM, which is now comparable to that of the non-diabetic 
population without metabolic syndrome. However, even if a tight intensive glucose control 
considerably reduced the diabetic complications, the study at 30 years of Nathan and 
colleagues showed that retinopathy (21%), nephropathy (9%) and cardiovascular (9%) 
complications are still present (39).  
A complete cure for diabetic patients might be the only effective treatment that can abolish 
these complications. Islets transplantation is limited to the number of islets available (at least 
until methods for generating functional islets will be available) and the necessity for 
immunosuppressive therapies. Stem cells, also derived from adult cell progenitors, could 
become a source of β-cells that can replace the human pancreas (40). However, another 
limitation in islets transplantation is the poor survival due to hypoxic necrosis. For this 
reason, research is conducted to find and develop several putative tools, such as for instance 
islets scaffold, to promote rapid neovascularization (41). 
Systemic approaches to decrease β-cell death in T1DM are immunosuppressive drugs, which 
cannot be used as a long-term treatment. Developing therapies are aiming to partly eliminate 
the immune cells specifically reacting against β-cell, acquire tolerance to the target β-cell 
antigens, or quenching inflammation. An intriguing possibility might be the modification of 
β-cells antigens to allow them to escape their destruction (41). 
T2DM patients are initially treated with lifestyle modification to reduce weight and increase 
muscle mass, with the goal to normalize blood glucose. Treatment failure leads to 
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pharmacological approach aiming at reducing insulin resistance in the liver and muscle, 
stimulate endogenous insulin release, reduce glucagon production, appetite and glucose 
uptake in the proximal tubules in the kidney. Along the traditional agents such as metformin, 
sulfonylureas, glinides, α-glucosidase inhibitors and glitazones, new treatments are emerging 
such as glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide 
(GIP) receptor agonists, and amylin agonists. If these drugs do not improve the metabolic 
control, the patients will start insulin treatment, which side effects are weight gain and risk of 
hypoglycemia.  
Several other approaches than improved glucose control have been tested to treat or prevent 
diabetic complications, but until now without clear success. Therapies aimed at lowering 
advanced glycosylated end products (AGEs) have been tried but stopped due to their toxicity, 
even though some testing is still on going. Inhibitors of aldose reductase targeting the polyol 
pathway were tested in clinical trials during the 80s and 90s but showed no beneficial or 
collateral effects. At the moment the only inhibitor of the above mentioned enzyme available 
in the market (Epalrestat) is approved only in Japan to treat symptoms of diabetic neuropathy 
with some beneficial effects on nerve conduction velocity (42). Protein kinase C (PKC) 
inhibitors exist but they also affect other ATP-binding kinases exerting toxic effects in vivo. 
Recently, a specific PKC-b inhibitor has shown a potential in reducing endothelial 
dysfunction and other complications (43). Although animal studies showed beneficial effects 
of antioxidant supplementation to delay the progression of diabetic complications (44, 45), 
antioxidant supplementation is still far from being successful as a therapeutic strategy in 
humans (46). 
1.2 THE MITOCHONDRION 
1.2.1 Structure and Organization 
The mitochondria are organelles composed of a double-membrane structure. The external 
membrane is permeable to small molecules and ions, which are able to move through proteins 
called porins, and to bigger molecules, which are actively transported by the translocase of 
the outer membrane (TOM). The inner membrane contains the components of the electron 
transport chain (ETC) and the ATPase complex and it is impermeable to molecules that do 
not possess a specific transporter. Inside the inner membrane the aqueous space called matrix 
contains all the oxidative pathways (beside the cytosolic glycolysis) that ultimately produce 
energy.  
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1.2.2 The Respiratory Chain 
1.2.2.1 Complex I or NADH:CoQ Oxidoreductase 
Also known as NADH dehydrogenase, it is composed of 45 polypeptide chains with one 
flavoprotein, FMN and at least 6 iron-sulfur clusters. The iron-sulfur proteins participate in 
redox reactions in which one electron at a time is transferred, using changes in the oxidation 
state of the iron atom. Complex I catalyze the exergonic transfer to CoQ of 2 electrons and 
one hydride ion (H-) from NADH and one proton from the matrix. In the reaction, 4 protons 
from the matrix are pumped into the intermembrane space. The CoQ is a small hydrophobic 
molecule that can diffuse freely in the lipid raft reaching the Complex III where it is oxidized. 
It acts as an electron bridge between less mobile electron carriers and can accept either one 
electron (semiquinone QH°) or two (ubiquinol QH2). Because this molecule transports both 
protons and electrons, it is very important in the process of coupling between proton 
movement and electron flux.  
1.2.2.2 Complex II or Succinate Dehydrogenase 
It is the only enzyme from the Krebs’s cycle associated with the inner membrane. It is formed 
by 5 prosthetic groups and 4 protein subunits: A and B contain 3 iron-sulfur clusters, a FAD 
and a binding site for the succinate, C and D are integral in the membrane and contain a heme 
b group and a binding site for the CoQ. The heme b group seems to be involved in the 
electron transfer but can decrease the frequency of the electron slip from the system. Other 
substrates can donate electrons without passing through CI e.g. Acyl-CoA dehydrogenase (to 
flavoprotein ETF and then to the ETF:CoQ oxidoreductase) and the glycerol-3-phosphate 
dehydrogenase that reduces the CoQ in a similar way as the succinate dehydrogenase.  
1.2.2.3 Complex III or bc1 Complex 
Complex III, known also as CoQ:cytochrome c oxidoreductase, couples the electron transfer 
from the CoQ to cytochrome c with the translocation of 4 protons for each electron couple. 
When the heme group of the cytochrome c accepts one electron from CIII, the cytochrome 
moves towards CIV to donate it to the binuclear copper center of this enzyme. The 
cytochromes are heme-containing proteins divided into 3 classes depending on their 
absorbance spectra (a, b, c). As for flavoproteins, the standard potential of reduction of the 
iron atom in the heme depends on its interaction with the side chains of the protein. The 
cytochromes a, b and c1 are proteins that integrate in the inner mitochondrial membrane, 
while the cytochrome c is a soluble protein that binds at the external membrane surface due to 
electrostatic interactions.  
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1.2.2.4 Complex IV or Cytochrome Oxidase 
This complex transports electrons from the reduced cytochrome c to reduce molecular 
oxygen to water. For every 4 electrons that flow through this complex, 4 protons are moved 
from the matrix to convert the oxygen into 2 molecules of water. The complex uses the 
energy from this redox reaction to pump a proton in the intermembrane space for each 
electron.  
1.2.2.5 Complex V or ATP Synthase 
ATP synthase is a large enzymatic complex in the inner membrane composed of two distinct 
subunits, one is integral in the membrane (Fo) and the other is peripheral (F1). F1Fo complex 
forms a protein channel that couples the transfer of protons from the positive side 
(intermembrane space) to the negative side (matrix). The F1 subunit alone catalyzes the 
hydrolysis of ATP while the two together catalyze the phosphorylation of ADP to ATP.  The 
equilibrium of the enzymatic reaction ADP + Pi to ATP is close to zero. However, due to the 
proton flow directed to the matrix, the ATP molecule is allowed to leave the enzyme after its 
synthesis.  
1.2.3 The Oxidative Phosphorylation (OXPHOS) 
The ultimate reaction of the ETC is the flow of electrons from NADH, succinate or other 
primary electron donors, through flavoproteins, ubiquinone (CoQ), iron-sulfur clusters and 
cytochromes to reduce the molecular oxygen. These transporters are in order of redox 
potential and the electrons tend to flow spontaneously along the ETC.  
The total amount of protons pumped from the matrix to the intermembrane space is 4 from 
CI, 4 from CIII and 2 from CIV for each couple of electrons transferred to the molecular 
oxygen. The resulting energy is called the proton motive force and can be divided into two 
components. The first component is the chemical gradient due to the different concentration 
of protons at each side of the inner mitochondrial membrane. The second one is an electrical 
gradient generated from the charge separation between the two sides. The resulting proton 
motive force allows the protons to flow back into the matrix through the ATPase at the same 
time using this energy to convert ADP to ATP.  
1.2.4 Replication of Mitochondria 
One to three copies of mitochondrial genome per mitochondrion and a total of 1000-10000 
per cell are compacted in structures called nucleoids (47, 48), which include mtDNA, 
mitochondrial transcription factor A (TFAM), mitochondrial single strand binding protein 
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(mtSSBP) and helicase Twinkle (49). Although much progress in understanding the 
regulation of mitochondrial genome has been made, the processes of mtDNA expression and 
replication remains largely unknown.  
TFAM is a nuclear encoded transcription factor imported in the mitochondria where it 
coordinates mtDNA packaging, transcription and replication. TFAM binds to specific 
mtDNA promoter sites with different affinity and to mtDNA at different ratios depending on 
the cell types (50). Its binding is very abundant in yeasts (every 15bp) where the TFAM 
concentration is predicted to be inhibitory, while in human epidermal carcinoma cells it is 
estimated to bind at every 1000bp (predicted to be stimulatory) (48). It has been shown that 
the transcription efficiency is similar between 1000bp to 20bp distance between TFAM 
molecules. At shorter distance (less than 20bp) there is a decline in mitochondrial transcripts, 
probably due to the packaging of mtDNA that becomes less accessible to the mitochondrial 
polymerase (51). Not only does the copy number of mtDNA depend on the amount of 
TFAM, but also TFAM amount depends on the mtDNA copy number (48). The degree to 
which human TFAM and polymerase are in excess for transcription in vivo is unknown.  
Recently, another mitochondrial transcription factor that stimulates transcription from the L-
strand promoter called mitochondrial transcription factor B (TFBM) has been discovered 
(52). Following research detected two different proteins in mammals (TFB1M and TFB2M) 
that interact directly with the mitochondrial RNA polymerase stabilizing the heterodimer 
complexes and activating the mtDNA transcription in the presence of TFAM (53). Further 
studies suggested that the two forms are not redundant. In fact, TFB2M has been related to 
the transcription of mitochondrial genes and mtDNA abundance while TFB1M seems to 
modulate mitochondrial translation (54, 55). 
The mtDNA encodes 37 genes necessary for mitochondrial replication machinery and 
maintenance. Only 13 of these genes encode for proteins involved in the ETC. Complex II is 
the sole complex completely transcribed from nuclear DNA. The transcription of mtDNA and 
other nuclear proteins necessary for mitochondrial functions involve a complex intracellular 
crosstalk. The nuclear master regulator of mitochondrial transcription is the peroxisome 
proliferator-activated receptor gamma co-activator 1-alpha (PGC1α). It can integrate cell 
stimuli and activates key transcription factors such as nuclear transcription factors 1-2 
(NRFs), estrogen-related receptor α (ERRα) and peroxisome-proliferator activated receptors 
(PPARs) (56).   
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1.2.5 Mitochondria in Diabetes 
Over the years, evidence that describes alterations in mitochondrial number, morphology or 
functions in diabetes has been accumulating. However, whether these mitochondrial changes 
are cause or consequence of the diabetic condition is under debate. Below are described in 
vivo evidence that link extra pancreatic mitochondrial alterations to diabetes and its 
complications.	 
1.2.5.1 Mitochondrial Alterations in Diabetic Subjects 
Most of the work in humans, trying to elucidate mitochondrial impairments in diabetes, has 
been performed in blood cells, muscle and kidney tissues due to ethical reasons and 
accessibility to the samples. 
To consider the spectrum of mitochondrial impairments during diabetes, it is necessary to 
separate T1DM from T2DM. In the latter, the high comorbidity with obesity and 
dyslipidemia, as well as insulin resistance, is a confounding factor that may lead to 
mitochondrial alterations. In fact, it is still not clear whether mitochondrial dysfunctions are 
cause of, or a consequence of insulin resistance. However, few works have pointed out that, 
at least in muscle, mitochondrial defects might be a consequence; for example, mice with 
progressive respiratory defects in muscle are not insulin resistant and mitochondrial 
impairments due to insulin deprivation in streptozotocin treated mice was partially reversed 
by insulin treatment (57, 58). Moreover, patients with severe insulin resistance due to genetic 
mutation of the insulin receptor gene display decreased phosphocreatine recovery, which is 
dependent of muscle mitochondrial metabolism (59). This is in line with another work in 
which 9 hours discontinuation of insulin in T1DM patients decreased rapidly mitochondrial 
ATP production and mitochondrial gene expression in muscle tissue (60). 
Ritov and colleagues showed that respiration, distribution and amount of mitochondria was 
reduced in muscle of T2DM subjects and correlated with insulin resistance (61). The same 
group also found altered mitochondrial morphology in T2DM muscle biopsies similar to 
obese subject (62). In another work, Patti and colleagues found a reduced expression of 
PGC1α and NFR in muscle of T2DM and again in insulin resistant prediabetic subjects (63). 
Moreover, in muscle biopsies, mitochondrial density and gene expression were decreased in 
offspring of diabetic patients. AKT and IRS-1 phosphorylation levels were suggested to be 
responsible, since no decrease in mtDNA, PGC1α or TFAM was detected (64). Taken 
together, these findings indicate a reduced number of mitochondria in muscle of T2DM 
patients, even though the impact of obesity is still not well understood. The effect of obesity 
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is important especially considering that a significant proportion of T2DM patients in Eastern 
countries are not obese. In a recent work studying mitochondrial dysfunction in subcutaneous 
adipose tissue of T2DM subjects, it was found that non-obese T2DM patients displayed a 
different pattern compared to obese T2DM patients. The authors found decreased activities of 
mitochondrial complexes, decreased Δψm and phosphorylation capacity in obese subjects and 
even more pronounced in obese diabetics compared to non diabetic and T2DM non obese 
patients (65).  
In insulin dependent diabetic patients, oxygen consumption supported by palmitoyl-L-
carnitine and glutamate in permeabilized atrial fibers showed reduction in Vmax, which 
correlates with the amount of HbA1c, without changes in mitochondrial number (66). 
Metabolomics in urine of T1DM and T2DM showed decreased mitochondria-derived 
metabolites in diabetic nephropathy along with decreased complex IV amount in kidney 
biopsies (67) and decreased mRNA transcripts of mitochondrial proteins (68).  
Leukocytes of prediabetic patients displayed a decrease in mtDNA copy number, which 
correlated with glucose during fasting (69). In contrast, Reiling and colleagues using blood or 
mouth samples from diabetic patients found that mtDNA was not associated with T2DM 
and/or blood glucose levels (70). This finding was confirmed in monocytes and lymphocytes 
of T2DM, in which an equal mitochondrial mass but altered morphology, Δψm and ROS 
production have been showed (71). In platelets from TD2M subjects decreased basal 
respiration, ATP production and an increase in antioxidant enzymes linked to high carbonyl 
levels have been found (72). 
Although results in different tissues, diabetes types and stages may lead to unclear 
conclusions on the role and features of mitochondria during diabetes in human, animal 
studies have helped to corroborate some results in humans. 
1.2.5.2 Mitochondrial Evidence in Animal Models of Diabetes 
Whereas mitochondria have been studied in T2DM patients, little is known about 
mitochondria in T1DM human tissues and most of the data derive from animal models of the 
disease. In OVE26 mice 100 days after the exacerbation of diabetes, heart isolated 
mitochondria displayed decreased respiratory control ratio, ultrastructural changes and 
modification of mitochondrial proteins (73). Streptozotocin treated rats displayed also 
abnormal heart mitochondrial morphology, decreased state 3 and maximal respiration. Insulin 
treatment was able to reverse the defects when it was introduced early after diabetes onset 
(74). Isolated mitochondria from liver of pancreatectomized rats displayed also decrease in 
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state 3 respiration in relation to the severity of diabetes (75). In streptozotocin induced 
diabetic rats a decline in complexes I-III has been shown during nephropathy (76-78). 
However, 12 weeks old Akita mice did not display changes in gene expression, protein 
expression or mitochondrial respiratory capacity in kidney tissue (79). The conflicting results 
could be explained by the different severity and characteristics of nephropathy in Akita mice 
depending on their genetic background and age (80). Moreover, in streptozotocin rodent 
models, decreased ATP output from mitochondria has been reported in kidney cortex during 
nephropathy (81), whereas the total kidney ATP was unchanged albeit 8 days after diabetic 
onset (82). In summary, mitochondria isolated from heart, liver and kidney of T1DM animal 
models mostly display dysfunctions in mitochondrial morphology, decrease in maximal 
respiration and ATP production. 
Regarding T2DM models, the most studied are the hyperleptinemic mice db/db. In kidney 
from 5 month old db/db mice, which develop diabetic nephropathy, an upregulation of 
complex I protein levels only has been found, along with decreased activity of complex III 
(83). Persson and colleagues found that in 4 months old db/db mice mitochondrial 
fragmentation and size was increased along with mitochondrial uncoupling in kidney cortex 
(84). The accumulation of triglycerides in the heart of 9 weeks old db/db mice increases 
mitochondrial biogenesis and mitochondrial volume in the heart. Using permeabilized fibers, 
it was shown a decreased state 3 respiration as well as decreased ATP synthesis and ATPase 
protein levels. In the same work, a fatty acid mitochondrial uncoupling mediated by UCP and 
partially ANT was also showed (85). In 16 weeks old db/db animals, reduced amount of 
mtDNA and OXPHOS activity has been found in muscle oxidative fibers and it was 
associated with increased intramyofibrillar lipids. However, in the same study the respiratory 
rates were higher in glycolytic muscle fibers with unaltered fat content (86). Choo and 
colleagues found that in white adipose tissue but not in liver or muscle, mitochondrial number 
and function was decreased, and morphology was altered in 12 weeks old db/db mice (87). 
Another study in 8 weeks old db/db and mice fed on high fat diet showed that the PPARγ 
agonist rosiglitazone reversed the decrease of mitochondrial gene transcription in adipose 
tissue (88). 
In muscle of high fat fed mice, mitochondrial decrease in number, transcripts, complex I 
linked respiration and β-oxidation as well as changes in morphology appeared only together 
with an insulin resistance state. In fact, when the mice were glucose intolerant but sensitive to 
insulin, no changes in mitochondria were found (89).  
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The inconsistent results reported above regarding mitochondria in humans and animal models 
of diabetes, in different types of cells and tissues show how important it is to rule out 
confounding effects. The most important are the comorbidity of diabetes with other 
conditions such as obesity, dyslipidemia and hypertension, and the different response 
between tissues. This is pivotal to understand the mitochondrial metabolic impact as cause of 
diabetes and its complications. 
1.2.6 Mitochondrial and Cellular Oxidative Stress in Diabetes 
1.2.6.1 Radical Species and Generations Sites 
Radical species are molecules, atoms or ions containing one or more orbital with unpaired 
electrons. They can be very small molecules or be part of macromolecules such as proteins, 
lipids, carbohydrates and nucleic acids. Some radical species are highly reactive while others 
are relatively harmless.  
The oxidative stress, and more recently nitrosative stress, can be defined as a perturbation of 
balance between pro-oxidant and antioxidant systems (90). ROS such as superoxide anion, 
hydroxyl radical and peroxyradicals, non-radical ROS such as hydrogen peroxide, oxygen 
singlet, as well as carbon, sulfur and nitrogen radicals are the variety of molecules that can 
induce cellular oxidative stress (91, 92). Every process that induce a reduction of one electron 
on the oxygen, produce a radical called superoxide anion. The subsequent or other partial 
reductions form oxygen singlet, a reactive form with paired electrons. The superoxide anion 
is continuously generated from some cellular processes, including ETC and microsome. In 
addition to that, xanthine dehydrogenase/oxidase and other intracellular oxidases can be 
important sources of this molecule. The ubiquitous presence of superoxide dismutase in 
cytosol and mitochondria ensure a fast clearance of the majority of this radical, converting it 
to hydrogen peroxide. Hydrogen peroxides are less reactive and can diffuse far from the site 
where they are generated. Main targets of this radical are the sulfhydryl group (thiols) part of 
the glutathione and several proteins. This reaction generates thiol-radicals (93). Hydrogen 
peroxide can also react with nitric oxide (NO) producing peroxynitrous acid that attacks 
cysteine, methionine and tyrosine in the protein (94). Transition metals such as iron and 
copper can react with superoxide anion generating the more reactive hydroxyl radical (95). 
This radical is considered to be the main toxic agent among the ROS because of its high 
reactivity with all biological macromolecules. This radical acts close to where it is generated, 
thus in most of the cases the damage is site specific. 
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Mitochondria are one of the main ROS generators. Although it was though that 1-2% of their 
electrons were diverted to generate oxygen radicals, this value has been revised and a lower 
estimated value has been proposed depending on the mitochondrial metabolic state (96). 
Eleven different sites with different properties are able to generate superoxide or/and 
hydrogen peroxide from catabolism and ETC. Complexes I and III are considered the main 
producer of ROS depending on the ETC state. Moreover, CI is known to produce ROS in the 
matrix while CIII produces ROS in both matrix and/or intermembrane space, depending on 
the generation site (90, 96, 97).   
1.2.6.2 ROS in Diabetes 
Patients with newly diagnosed T1DM followed for 3 years showed increased levels of 
nitrosative stress in plasma that correlates with the glycemic control (98). Moreover, T1DM 
patients with short duration of the disease (5-6 years) and no dyslipidemia, displayed 
decreased total plasma antioxidant levels, increased conjugate dienes and lipid 
hydroperoxides (99). Lymphocytes extracted from insulin-dependent diabetic patients with 
variable disease duration, are characterized by increased DNA damage that correlates with 
serum glucose levels (100). Measuring 8-Oxo-2'-deoxyguanosine (8-OHdG) as marker for 
oxidative stress in mononuclear cells, Dandona and colleagues found a 6 and 4 fold increase 
in T1DM and T2DM patients respectively (101). Strong evidence supports the notion of an 
excess of ROS during diabetic nephropathy (102). However, the site of production is still 
under debate and late results are challenging the common thought that mitochondrial 
superoxide is the primary source (103). The actual methods and the difficulty to demonstrate 
the ROS generation site limit the understanding of the mitochondrial involvement in ROS 
production (104).  
The importance of ROS in the progression of diabetic complications (nephropathy and 
neuropathy) is further demonstrated by works in which antioxidant treatments were able to 
delay these complications in db/db mice (45, 84, 105). Cameron and colleagues showed that 
treatment with the antioxidant β-hydroxitoluene prevents the nerve dysfunction in 
streptozotocin rats after 2 months of diabetes (106). Mitochondria isolated from retina of 
streptozotocin mice have increase ROS production and impairment of CIII that was alleviated 
by overexpression of SOD in transgenic mouse model (107). 
1.3 PRIMARY CILIUM 
Over the last two decades, primary cilia have emerged as important hubs of cellular signaling. 
Whereas in invertebrates such as Drosophila melanogaster and Caenorhabditis elegans, 
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primary cilia are primarily found in sensory neurons, roughly 80% of the cells in the 
vertebrate body are ciliated. The primary cilium is a protrusion from the cellular membrane 
which functions in sensing the extracellular environment (i.e. photoreceptor, olfactory 
neurons, kidney epithelial cells) and is also involved in several signaling pathways during 
development and tissue homeostasis (108). Mutation in genes encoding for ciliary proteins 
cause developmental defects (neural tube closure) for example by altered Hedgehog signaling  
due to the attenuated signal transduction at the cilium (109, 110). Moreover, disrupting 
primary cilia or knocking down several genes associated with the ciliopathy Bardet-Biedl 
Syndrome (BBS) result in an over activation of the Wnt pathway suggesting that the cilium is 
necessary to restrain this signaling pathway (111, 112). Whereas the importance of ciliary 
signaling is well recognized during development, the impact of cilia in adult tissue 
homeostasis is still largely unexplored. Recently, ciliary function has been recognized as 
important for the mTOR signaling (113-115) and autophagy (116, 117).  
1.3.1 Structure 
Cilia are assembled and reabsorbed from their distal part or tip. Because there is no protein 
synthesis in the ciliary compartment, transport mechanisms are essential for cilia formation 
and maintenance carrying ciliary proteins to 
and from the basal body (Fig.1). Cargos, which 
carry the proteins, are actively transported 
along the axoneme by intraflagellar transport 
proteins (IFTs). The IFT machinery was 
discovered first in Chlamydomonas reinhardtii 
and its impairment leads to absence or defects 
of the cilium or flagellum itself (119). IFT 
particle B is a multimeric protein complex that 
mediates anterograde transport to the 
flagellar/ciliary tip by attaching cargo to cilia-
specific kinesin-II motor proteins. Retrograde 
transport, from the tip to the basal body, is 
dependent on IFT particle A and cytoplasmic 
dynein I. At the basal body, several BBS 
proteins have been implicated in the modulation of ciliary trafficking together with other 
ciliopathy proteins (120). Two mechanisms are responsible for protein entry into the ciliary 
compartment: movement of membrane proteins (or receptors) and cytosolic proteins. Some 
 Figure 1. Structure and transport in primary cilia (118). 
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membrane components can reach the ciliary membrane by moving in the lipid bilayer at the 
side of the cilium, while cytoplasmic proteins pass through a region called transition zone 
which is where the basal body transitions to the ciliary axoneme. Here, the structure of the 
basal body formed by nine microtubular triplets change to the ciliary structure formed by nine 
microtubular doublets. Recent works have identified different classes of proteins involved in 
gating cytoplasmic proteins such as ciliopathy gene products, nucleoporins and septins (121, 
122). Moreover, entry of proteins above the ciliary size barrier can occur in a similar manner 
to the one used in the nucleus that involves small G protein Ran (123).  
Cilia assembly and disassembly is linked to the cell cycle. They are assembled in G0-G1 
phase and disassembled before the starting of mitosis. Cilia length and morphology is specific 
for cell type and tightly regulated. However, cilia length can be modified by several 
mechanisms including tubulin post-translational modification, IFT proteins, intracellular 
calcium, guanylate and adenylate cyclase and several signaling pathways such as protein 
kinase A, MAP kinase and mTOR (124).   
As mentioned before, cilia formation, maintenance and function are dependent on molecular 
trafficking to and along the ciliary axoneme. Kinesin (anterograde) and dynein (retrograde) 
motors hydrolyze ATP to produce the energy necessary for their movement, while protein 
sorting and trafficking at the basal body involves GTP/GDP equilibrium (Ras GTPase 
superfamily) (125, 126). Cellular energy depletion can directly affect motor proteins that use 
ATP such as kinesin and dynein and GTPases involved in transport and import of ciliary 
protein such as Rheb and Ras (125-127).  
1.3.2 Ciliopathies and the Link to Diabetes  
More than 1000 proteins were identified and classified in the ciliary proteome. Current 
knowledge evidence that mutation in one of the 40 specific ciliary genes give raise to a 
spectrum of disorder called ciliopathies. The ciliopathies are a heterogeneous class of 
disorders that displays different or similar phenotypes depending on the original mutation 
(Table 1). The most common manifestations of the disease are retinal degeneration, renal 
cysts and cerebral abnormalities. However, two ciliopathies such as BBS and Alström disease 
present obesity and high comorbidity with diabetes.  
BBS is an autosomal recessive disease with prevalence between 1:13.500 and 1:175.000. Up 
to now, 16 different loci that account for 80% of the syndrome have been identified (128). 
The clinical manifestations are commonly visible in the first decades of life. Polydactyly 
affects more than half of the patients and is detected at birth, while the rode-cone dystrophy 
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presenting as retinitis pigmentosa is present in 
almost all patients and causes blindness (129, 
130). Developmental delay, cognitive defects, 
speech deficits, ataxia, renal cysts are among the 
most common signs together with obesity. 
Truncal obesity is visible in the first year of life 
on one third of the subjects and present in the 
majority of the patients later on. It has been 
suggested that as secondary effect of metabolic 
syndrome and insulin resistance, these patients 
develop T2DM (128, 129). An early study 
described that almost half of BBS patients were affected by diabetes, whereas another work 
reported diabetic prevalence of 6% (129, 130). However, the authors themselves speculated 
that an underestimation was possible due to the low number of patients tested. Moreover, the 
age of the patients can be a discriminant and the diabetic phenotype can be developed at later 
age.   
Alström syndrome is a rare disease (around 300 known cases) caused by a mutation of a gene 
encoding for a protein (ALMS1) that localizes in the centrioles and basal body and might be 
involved in calcium signaling (132). The mutation causes developmental retardation without 
cognitive defects, kidney failure before adulthood and cardiac failure. Moreover, patients can 
develop T2DM as early as the age of 5 and 82% of the patients over 16 are diabetic (133). 
Autosomal polycystic kidney disease has been linked to primary cilium impairment and 
signaling even though the causal relationship is still not clear (134). The disease has 
prevalence <5:10000 and is characterized by renal cysts and extra-renal manifestations (135). 
Dialysis or kidney transplantation is required in these patients. In subjects with normal renal 
function, it has been reported that OGTT as well as fasting glucose were significantly higher, 
suggesting lower insulin secretion (136). However, other studies found insulin resistance and 
a normal plasma fasting glucose (137). 
Table 1. Phenotype spectra of ciliopathies (131). 

 21 
2 GENERAL AIMS 
This thesis aimed to study the role of the mitochondrion and primary cilium in the 
pathophysiological mechanisms of diabetes and its complications. Further, we aimed to 
clarify the mitochondrial and cellular metabolism in response to different oxygen tension 
regarding islets function, in the context of therapeutic approaches to improve islets survival 
during transplantation.  
2.1 SPECIFIC AIMS 
1. Clarify the mitochondrial and metabolic response to acute and/or chronic 
hyperglycemia and hyperosmosis in primary human cells. (Study I) 
2. Study the effects in vitro of hypoxia and hyperoxia on mitochondria, energy 
metabolism and insulin secretion in pancreatic islets and exploring islets pre-
transplantation treatments using diazoxide and high oxygen tension to reduce the 
negative impact of hypoxia. (Study II and III)  
3. Provide a possible link between insulin signaling, diabetes development and primary 
cilia and elucidate the role of mitochondrial function and cellular energy balance on 
ciliary maintenance. (Study IV and study V/preliminary results) 
4. Understand the impact of mtDNA depletion linked to diabetes on mitochondrial 
bioenergetics. (Study VI/preliminary results) 
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3 MATERIALS AND METHODS 
3.1 CELL CULTURE AND TREATMENTS 
All chemicals were purchased from Sigma-Aldrich (St. Louis, U.S.). Primary Human Dermal 
Fibroblasts (HDF) and Human Dermal Microvascular Endothelial cells (HDMEC) isolated 
form healthy donors were purchased from Promocell GmbH (Heidelberg, Germany). To 
avoid donor specific phenotype, three different donors for HDF and two for HDMEC were 
used. HDF were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 1g/L glucose, 
L-glutammine and pyruvate supplemented with 10% heat inactivated FBS (Gibco, Waltham, 
U.S.), penicillin 100UI/ml and streptomycin 100µg/ml. HDMEC were cultured in endothelial 
cell growth medium MV supplemented with growth factor (Promocell), penicillin 100UI/ml 
and streptomycin 100µg/ml. Cells between passages 4-9 or earlier than 20 population 
doublings were used and media was changed every other day. For experiments performed 
after one week of treatments (called long-term experiments), cells were incubated with 
different concentration of glucose or mannitol as follows: control C (5,5 mM glucose), 
hyperglycemia HG (27,5mM glucose) or hyperosmotic control M (5,5 mM glucose + 22mM 
mannitol). New batches of media were prepared every other week to avoid sugars 
concentration errors. Mouse cardiomyoblast cell line (H9c2) were cultured in DMEM 4.5g/L 
glucose, L-glutammine and pyruvate supplemented with 10% heat inactivated FBS, penicillin 
100UI/ml and streptomycin 100µg/ml. Mouse insulinoma cell line (min6m9) were donated 
from Seino´s lab (Kobe University, Kobe, Japan) and cultured in DMEM 1g/L glucose, 
supplemented with 10% FBS, penicillin 100UI/ml, streptomycin 100µg/ml and 50µM β-
mercaptoethanol (Gibco). Mouse inner medullary collecting duct cell lines (IMCD3) were 
donated from Berggren´s group (Karolinska Institute, Solna, Sweden) and Lickert´s lab 
(Helmholtz Center Münich, Neuherberg, Germany). IMCD3 were grown in DMEM F:12 
(Gibco) supplemented with 10% FBS, penicillin 100UI/ml and streptomycin 100µg/ml. 
Human telomerase reverse transcriptase immortalized retinal pigmented epithelial 1 cell line 
(RPE1) was purchased from ATCC (Manassas, U.S.). RPE1 were grown in DMEM F:12 
(Gibco) supplemented with 10% FBS and 0.01 mg/ml Hygromycin B. For all the experiment 
during confluence, 20000 cells/cm2 were plated at day 0 and allow reaching confluence until 
day 4. The same day the cells were starved using 0.5% FBS until day 7. The cells were than 
treated according to the experiment using the medium supplemented with 0.5% FBS. Human 
Embrionic Kidney (HEK) 293A and 293FT were used for viral production. 293A were grown 
in DMEM 4.5g/L glucose, 10% FBS, penicillin 100UI/ml and streptomycin 100µg/ml while 
293FT in DMEM 4.5g/L glucose, 10% FBS, 0.1mM MEM (NEAA), 6mM glutamine, 1mM 
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sodium pyruvate, P/S, geneticidin 500µg/ml.. HeLa cells were grown using the same medium 
and were used for testing the non-replication of viruses. All cells were incubated at 37° and 
5% CO2 and passaged before confluence. 
3.2 MOLECULAR BIOLOGY 
3.2.1 Short Hairpin RNA 
To silence the expression of genes of interest we designed short hairpin mRNA (shRNA) 
(Dharmacon siDESIGN centre, GE Healthcare, Munich, Germany). We used the accession 
number of the genes of interest (NCBI Reference Sequence: Tfam NM_009360.4, Ift88 
NM_009376.2) and selected 3 possible candidates (open reading frame ORF and two 
untranslated region after the stop codon 3´UTR) with high score value after blasting the 
sequence for mus musculus. The oligonucleotides were purchased from Eurofins Operon 
(Huntsville, U.S.) after some necessary modifications to successfully integrate the double-
stranded oligonucleotides into the chosen vector. We changed uridin with thymidine bases 
and removed the last two uridin bases to avoid degradation of the shRNA. We added to the 
oligonucleotide sense strand a short sequence (CACC) at the 5´ and an additional guanidine 
as starting nucleotide. To form the shRNA loop we added a sequence at the 3´ (GAGA). To 
form the double strand oligonucleotide we designed a complementary oligonucleotide with 
addition of AAAA at 5´ and the rest complementary to the top strand but the CACC 
sequence. The shRNA used for the experiments were generated with the oligonucleotides 
listed in Table 2.  
Oligonucleotides Sequence 5´-…-3´ Strand 
Ift88 CACCGTGTTAAACCTGGATCAAATGAGAATTTGATCCAGGTTTAACA Sense 
 AAAATGTTAAACCTGGATCAAATTCTCATTTGATCCAGGTTTAACAC Antisense 
Tfam CACC GTGTCAAACTAGAACGGATA GAGA TATCCGTTCTAGTTTGACAC Sense 
 AAAA GTGTCAAACTAGAACGGATA TCTC TATCCGTTCTAGTTTGACAC Antisense 
LacZ CACCGCTACACAAATCAGCGATTTCGAAAAATCGCTGATTTGTGTAG Sense 
 AAAACTACACAAATCAGCGATTTTTCGAAATCGCTGATTTGTGTAGC Antisense 
Table 2. Oligonucleotides used to generate shRNA. 
 
After plasmid delivery into the cells, cellular dicer complex cleaves the transcribed sequence 
and the 5´ part will bind the mRNA of interest (Tfam or Ift88). The RNA-induced silencing 
complex (RISC) will then binds the mRNA complexes and will destroy it, thus silencing the 
information.  
The entry vector kit BLOCK.iT U6 RNAi (Invitrogen, Waltham, U.S.) was used to generate 
the plasmid for shRNA delivering. The annealing of the oligonucleotides (Table 2) was 
performed at room temperature (rT) adding: 5µl top and 5µl bottom strands (200µM final 
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concentration), 2µl 10x oligonucleotides annealing buffer and 8µl DNAse/RNAse free water. 
The microfuge tubes were incubated 4 min 95° and then at rT 10 min. After brief 
centrifugation and gently mixing we diluted the oligonucleotides solution 100 times in H2O 
(resulting in 500nM concentration) and then again including 10% annealing buffer 10x (final 
concentration 5nM). The annealed double strand (ds) oligonucleotides were stored at -20°. 
Each ds oligonucleotide was inserted into the pENTR/U6 vector. The ligation at rT was 
performed adding in the following order: 4µl 5x ligation buffer, 2µl pENTR/U6 (0.5ng/µl), 
1µl ds oligonucleotides 5nM, 12µl H2O and 1µl T4DNA ligase. The reaction was incubated 
2h and the ligation product stored at -20°. Subsequently, 2µl for each ligation were added to a 
tube of competent TOP10 E.coli  (Invitrogen). The tubes were incubated 30 min on ice and 
heat shocked 30 sec at 42°, returned on ice for 2 min and 250µl of SOC medium (0.5% yeast 
extract, 2% triptone, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, sterile glucose 20mM) at rT 
was added. The tubes were shaken at 200rpm 37° 1h and 100µl of bacteria were spread in 
pre-warmed agar plates (15g liquid broth (LB) in 600ml H2O) with kanamycin (0.1mg/ml) as 
resistance for selection. After overnight incubation at 37°, 3 single colonies for each plate 
were picked for plasmid expansion and characterization. Each single colony was transferred 
into a tube containing 5ml LB with 0.1mg/ml kanamycin and left in the shaking rotating 
incubator at 37° overnight. The day after, 300µl of bacterial suspension and 500µl sterile 
80% glycerol in deionized H20 were used as stock (stored at -80°) and the rest of bacterial 
suspension for plasmid purification carried out with geneJET plasmid miniprep commercial 
kit (Invitrogen). The plasmids were sequenced using the primer M13rev (Table 3) to ensure 
that the ligated sequence was correct. 
3.2.2 Virus Generation 
3.2.2.1 Recombination 
We recombined the shRNA sequence using the entry clone pEntr/U6, in both pAd/BLOCK-
iT for adenoviral and pLent/Block-iT destination vector for lentiviral production. The 
recombination was possible due to the enzyme mix LR clonase that cut two sites flanking the 
shRNA inserted in pEntr/U6 and recombines it into the destination vector. The reaction was 
performed at rT by adding and mixing: entry clone 1-7µl (50-150 ng), destination vector 1µl 
(150ng/µl), sterile Tris-EDTA (TE) buffer, pH 8 up to 8µl (1L: 10ml 1M Tris and 2ml 0.5M 
Na2EDTA). The LR clonase was thawed and mixed 2 min on ice, vortexed twice 2 sec and 
2µl to each reaction were added. After overnight incubation at 25° the reaction was blocked 
using 1µl of proteinase K 10 min at 37°. The plasmid was then transferred in competent 
 26 
E.coli. True expression clones were ampicillin resistant (100µg/ml) and chloramphenicol 
sensitive (30µg/ml). Preparations from single clones were sequenced using the primers 
Adenorev and Lentirev listed in Table 3.  
Primers for sequencing Sequence 5´-…-3´ 
pENTR/U6 (sequencing) GGACTATCATATGCTTACCG 
pAd/BLOCK-iT (sequencing) CCTTAAGCCACGCCCACACATTTC 
pLent/Block-iT (sequencing) ACCGAGGAGAGGGTTAGGGAT 
ORF Mito-PAGFP Forward NNNGCGGCCGCGCCACCATGTCCGTCCTGACGCCGCTGCTGC 
ORF Mito-PAGFP Reverse NNNGGCGCGCCCTTGTACAGCTCGTCCATGCCGAGAGTG 
Table 3. Primers used for sequencing the plasmids to verify the correct insertion of shRNA and to amplify Mito-PAGFP 
ORF. 
3.2.2.2 Adenovirus 
The purified pAd/BLOCK-iT destination vector was digested overnight to expose the left and 
right inverted terminal repeats (ITRs) to allow proper viral replication and packaging (10µg 
with 3µl of PacI enzyme (Thermo Scientific, Waltham, U.S.).  
After purification the cut vector was shuttled into HEK293A (HEKA) cells. We seeded 
1.3x106 cells at day 0 in 6 well plates in growth medium with antibiotics. At day 1, we 
changed the medium adding 1.5ml of the one without antibiotics and transfected the cells 
adding 1µg of digested plasmid. At day 2, the medium was replaced with complete growth 
medium and at day 3, cells from each well were transferred into a 10cm dish. The medium 
was changed every 2-3 days until cytopathic effects (CPE) were observed (between day 10 
and 13). In this moment the cells and the medium were collected. To purify the virus, tubes 
containing the cells and adenoviral suspension were placed at  -80° for 30 min and then at 37° 
for 15 min. This procedure was repeated twice to cause cell lysis allowing the release of all 
virus particles. The tubes were centrifuged 3000 rpm 15 min and the supernatant aliquot and 
stored at -80°. 
To generate a viral higher titer (107-8 to 108-9), it was necessary to amplify the crude lysate. 
HEKA cells were plated 24h before the transduction in 10cm dishes at concentration of 3x106 
cells. After addition of 100µl of crude lysate, cells were incubated until the infection reached 
80-90%, which was recognizable when the cells have rounded up and were floating or lightly 
attached to the dish (typically 2-3 days after infection). The virus was harvest as before.  
To measure the virus titer, 1x106 HEKA cells were plated at day 0 into 6 well plates. At day 
1, virus serial dilutions from 10-4 to 10-9 were prepared and added to the wells. After 
overnight incubation the medium was removed and 2ml agarose solution (12ml of 
prewarmed 37° medium and 1.2ml of 65° 4% agarose) was gently overlaid to the cells. The 
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plate was returned back into the incubator after 15 min. At day 6-7 another 1ml of agarose 
medium per well was added. When the plaques were visible (around day 10-14) we applied 
for each well 300µl of 5mg/ml thiazolyl blue tetrazolium (MTT), waited 3h and counted the 
plaques. The titer was determined counting the number of plaques using a specific dilution of 
the virus. The titer was approximately 2-3x108. Knowing the titer we calculated the 
multiplicity of infection (MOI), which is the amount of viral particles that will enter one cell 
(viral particles/cells infected). We seeded IMCD3 cells in a 48 well plates and added different 
volumes of crude virus. We aimed to have a lowest MOI that give us the best gene knock 
down (KD), to minimize the possibility of phenotype changes. We used MOI of 0.5-1-2-5-
10-20-50 to determinate the optimal degree. We transduced the cells of interest and measure 
the mRNA KD at the desired time point. We identify in MOI 15 the amount of virus that 
gives us maximum KD with the minimum amount of virus. 
To ensure the replication deficiency of the adenovirus outside their competent cells (HEKA) 
we seeded 1x106 IMCD3 in 10cm dishes. The day after we added the crude lysate on the cells 
and the following day we used one new plate of HEKA in which we added again crude lysate 
and one in which we added the third PBS wash of the IMCD3 cells. After three days HEKA 
cells treated with crude lysate were not attached while the one treated with the supernatant 
(third wash) were unaffected. This experiment proved the absence of virus after the wash. 
Moreover, the fact that the IMCD3 cells after virus treatment did not lyse implied an absence 
of viral replication. 
3.2.2.3 Lentivirus  
To produce the virus we used HEK293-FT that stably expresses a hexamer protein allowing 
optimal virus production, namely dominant-acting oncoprotein derived from the 
polyomavirus SV40 (SV40 large T antigen) under the control of cytomegalovirus (CMV) 
promoter. The pLenti6/Block-iT destination vector contains elements required to allow 
packaging of the expression construct into virions and a blasticidin resistance sequence to 
allow generation of stable cell line. Moreover, it has a deletion in LTR viral promoter that 
results in a self-inactivation of the lentivirus after transduction. ViraPower Packaging Mix 
contains mixture of three packaging plasmids (pLP1,2, VSVG) for structure and replications 
of the virus.  
At day 0 we diluted 3.3µg of ViraPower Packaging Mix and 1.1µg of pLenti-DEST in 550µl 
Optimem. In a separate tube we diluted 13.2µl Lipofectamine 2000 (Invitrogen) in 550µl 
Optimem and incubated 5 min. We then combined the solutions and waited 20 min. Next, we 
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added DNA Lipofectamine complex to the plate containing 2ml of media without antibiotics 
and pyruvate, and 2.2x106 cells. At day 1, the medium was replaced with 3ml of complete 
culture medium. At day 4, the supernatant containing the virus was harvested and centrifuged 
3000rpm 5 min, aliquot and stored at -80°.  
To verify the absence of viruses after the wash we plated 2x105 min6m9 and transduced 
them. After the overnight incubation, the medium was removed and 1ml of the first and the 
third wash were added to HeLa cells plated the day before into a 6 well plate (1x106 in 1ml 
medium). After two days of incubation the cells were treated with 5µl/ml of blasticidin. After 
5 days the cells treated with the third wash were dead while the one treated with the first wash 
displayed some colonies, showing that after the third wash the medium was free from viruses.  
To calculate the rate limiting dilution of the virus (RLD) we used a method similar to the one 
used for measuring the adenovirus titer. At day 0, we seeded 2x105 HEKA. The day after we 
diluted 100µl of crude viral stock in 900µl medium adding polybrene, which facilitates the 
binding between viral envelope and cellular membrane (final concentration 4-8µg/ml). We 
treated the cells with 600µl (in 12 well plates to increase viral concentration in proximity of 
the cells) of crude virus diluted between 10-3 and 10-7. At day 2, cells were washed 2 times in 
PBS and the medium was changed. At day 3, cells were split in 6 well plates and the 
following day the medium was supplemented with blasticidin. Cells were then passaged at 
low density and after 5 days the formed colonies were stained with MTT or Cristal violet. 
The RLD is the number of colonies multiplied by the dilution factor (e.g. 10 colonies in 10-5 
virus dilution = RLD 106). 
3.2.3 Cloning  
Mito-PAGFP (Addgene #23348 (138)) plasmid was used to amplify its ORF with primers 
listed in Table 3, designed using clone manager (Sci-ED software, Morrisville, U.S.). At the 
5´ end of the forward primer we added a sequence compatible with the enzyme cutter NotI 
followed by a Kosak sequence. In the reverse primer we added at the 5´ end a sequence 
compatible with the enzyme cutter AscI. We then used 100pg of plasmid Mito-PAGFP and 
amplified the ORF with Phusion hot start II DNA polymerase (Invitrogen). The product was 
stored at -20° and 5µl were used to verify the correct amplification of the sequence (agarose 
gel 1%).  
We cut the amplification product at the NotI and AscI sites and purify it (QiaQuick, 
Hombrechticon, Switzerland). As vector to insert the Mito-PAGFP sequence we used the 
plasmid pCAG-2A-Arl13b-TagRFP kindly donated from Dr. Ingo Burtscher (Helmholtz 
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Center Munich). This plasmid contains two cutting sites (NotI and MluI) compatible with the 
ones we generated outside the sequence of Mito-PAGFP (NotI and AscI). Thus, the plasmid 
(6-8 µg of vector) was cut using NotI and MluI adding 10µl buffer and 1.5µl each enzymes to 
100µl total reaction. The reaction was left at 37° overnight. After DNA purification we 
loaded 100ng of the cut vector in agarose gel 0.7% to check that the plasmid was singularly 
cut. To ligate the amplified fragment with the open vector we used in a total volume of 10µl: 
200ng vector and 2.5 times of the fragment (calculated in molecules) as follows: Mito-PaGFP 
(839bp) and pCAG vector (8508bp); amount of insert: 839/8508 x 200 x 2.5 = 49.3 ng. The 
ligation was carried out overnight at 14° followed by 2h at rT using 1µl T4 ligase 
(Invitrogen), 1µl T4 buffer and 8µl of the combined vector, insert and water. We then 
transformed competent E.Coli using 2µl ligation in carbonicillin-enriched plates. The day 
after, we picked at least 30 colonies, let them grow overnight and made preparation to 
identify the colonies expressing the plasmid of interest. To do that we cut (2h 37°) the 
plasmid several times inside and outside the Mito-PAGFP ORF sequence with BSerI 
restriction enzyme. The predicted band size of the correct ligation pCAG-MitoPAGFP-2A-
Arl13b-TagRFP separated in 1.5% agarose gel were 1114, 1316, 1503, 1885, 3529bp while 
the bands of the plasmid in which the insert did not ligate were 1316, 1503, 3529, 2167bp. 
We selected 3 candidates to verify the point mutations of our insert by sequencing. We 
linearized the plasmids before using them for transfecting the cells of interest, digesting 
overnight 10µg of the three ligations using the single cutter enzyme ScaI. After purification, 
1,6µg of each plasmid were bound to lipofectamine and the solution transferred into the 
culture dish. 2x105 IMCD3 or min6m9 cells were seeded in 12 well plates the day before the 
transfection. The transfection medium was changed after 7h with normal growth medium and 
after 48h 1µg/ml puromycin was added to induce selection. 
3.3 METABOLIC ANALYSIS 
3.3.1 Seahorse Metabolic Flux Analysis 
Metabolic flux analysis was performed using Seahorse XF24 or XF96 Extracellular Flux 
Analyzer (Seahorse Biosciences, Billerica, U.S.). The cells were incubated at 37°C without 
CO2 1h prior all the experiments. Running template for all cellular experiment was: 2 min 
mix, 1 min wait and 2 min measures. 
In Paper I, 1.5x103 HDF or HDMEC/well were seeded and allowed to reach confluence. The 
day of the experiment the growing medium was replaced with XF medium (as specified by 
Seahorse bioscience) containing 2mM GlutaMax (Gibco), 1mM sodium pyruvate, glucose or 
 30 
mannitol (see 2.1), 2% FBS (HDF) or 1.8 ml of MV growth factors (HDMEC). In the acute 
treatment experiments, we measured the respiration at basal level and after injection of 
glucose or mannitol. In the long-term treatment experiments, we measured the respiration at 
basal level in their respective media, and following injection of oligomycin (final 
concentration 1 µM), carbonylcyanide 4-trifluoromethoxy-phenylhydrazone (FCCP 4-6 µM), 
and antimycin A (8 µM). Careful titration was conducted to know the concentration of 
chemicals to use. The high concentration of FCCP and antimycin were due to the presence of 
serum in the assays, which partially quenches these chemicals. For long-term experiments the 
data were normalized on the number of cells per well, while for acute treatment data are 
presented as comparison against basal oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). Normalization was carried out staining the nuclei at the end of the 
experiment with Hoechst 33342 (Molecular Probes) for 10 min and imaged using BD 
pathway 855 (BD Biosciences, Franklin Lakes, U.S.) (10x objective, montage 5x4, λex/em 
405/425-475). The number of cells per well was quantified using cell profiler software 
(Broad Institutes, Cambridge, U.S.). 
In Paper IV and preliminary data, 3x104 min6m9 cells/well were seeded two days after viral 
transduction. The day after, the growing medium was replaced with XF medium containing 
2mM GlutaMax, and 2% FBS. The respiration was measured before (baseline) and after 
addition of glucose (11mM final concentration).  
In experiments on IMCD3 and RPE1 (preliminary data), 5000 cells/well were seeded and 
treated (see 2.1). The day of the experiment the growing medium was replaced with XF 
medium containing 2mM GlutaMax, 1mM sodium pyruvate, 16mM glucose and 0.5% FBS. 
We measured the basal OCR and ECAR and after injection of different concentrations of 
oligomycin, rotenone and rotenone + antimycin (4µM final each). Data are presented as 
comparison against basal OCR and ECAR.  
In Paper II and III, 70 size-matched rat islets were washed in XF containing 3,3mM glucose, 
2mM GlutaMax, and 1% FBS and plated in a specific 24 well plate for islet measurement 
(Seahorse Bioscience) with 500µl medium. The total time between preparation and first 
measurement was between 2 and 3 hours. The running template for the measurement was: 2 
min mix, 1 min wait and 4 min measures. We measured the basal OCR and after injection of 
glucose (final concentration 16,7mM), oligomycin (8 µM), FCCP (1µM) and antimycin A 
(10µM). 
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3.3.2 Polarographic Assay  
HDF and H9c2 cell lines were allowed to reach confluence, detached, harvested, suspended 
in their respective media (see 2.1) and assayed for oxygen consumption at 30°C in DMEM 
1g/L glucose, 1mM pyruvate, 2mM Glutamax and 2% FBS using a thermostatically 
controlled 1,6 ml chamber (Instech, Plymouth Meeting, U.S.). After recording basal 
respiration for approximately 4 min, 35µl of either medium or 1M glucose or mannitol were 
injected and the respiration was monitored for the following 5 min. Approximately 1.5-2x106 
HDF and H9c2 were used and counted with hemocytometer. 
3.3.3 Glucose Uptake 
Two days after viral transduction, 2x105 min6m9 cells/well were seeded in growing medium 
and starved overnight in Optimem. The following day the medium was replaced with 
Optimem containing 11mM glucose and 5µl/ml deoxy-D-glucose, 2-[1,2-3H(N)] (Perkin-
Elmer, Waltham, U.S.) for 1h. The cells were washed 3 times with PBS and 400µl of lysis 
buffer (1%SDS in 0.1M NaOH) were added. The lysate was shaken for 1h and recollected. 
The radioactive count was performed using a Wallac 1409 liquid scintillation counter 
(Perkin-Elmer). Glucose levels were normalized to Accublue DNA determination (Biotium, 
Freemont, U.S.). 
3.3.4 Adenosine and Pyridine Nucleotides Content 
Adenosine and pyridine nucleotides were extracted and separated using a modified version 
of the previously described method (139). For the acid extraction, cells were washed once in 
PBS and 700µl ice-cold perchloric acid 1M every 10cm dish was added. The plates were 
immediately frozen on dry ice and store at -80°. Cells were scraped on ice and the suspension 
collected in microfuge tubes. After centrifugation at 14000xg at 4° 10 min the supernatant 
was neutralized using KOH 20M and phosphate buffer (50ml 12g KH2PO4 and 2.1g K2HPO4 
pH 7) and returned back at -80° for 30 min. The solution was thawed on ice and centrifuged 
as before. The supernatant was collected and 50µl were injected in the HPLC. Basic 
extractions was carried out detaching the cells with trypsin and suspending the cellular pellet 
in 200µl of H2O and 20µl of cold solution 0,5M KOH, 50% vol/vol ethanol and 35% wt/vol 
CeCl. The tube was kept on ice for 5 min and centrifuged at 14000xg 15 min at 4°. 100µl of 
supernatant was then directly injected in the HPLC. 
In Paper I we used a reverse phase Kinetex C18 column 250x4.6mm/5µm (Phenomenex, CA, 
U.S.) in a HPLC Waters 510 system. Absorbance at 260nm was monitored using a 
photodiode detector (Waters 996, Milford, U.S.). For measurement on IMCD3 and RPE1 
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(preliminary results), the separation module used was a Waters 2795 (Waters) equipped with 
Supelcosil LC-18 15cmx4,6mm/3µm column, guard column and Waters 2996 photodiode 
array detector 294 (Waters). 
The mobile phase used for separation consisted of sonicated and filtered (45µm) Buffer A 
(23,3mM KH2PO4, 1,7mM K2HPO4, 10mM tetrabuthylammonium sulfate, pH 5.7) and B 
(Methanol HPLC grade Promochem, Germany). The gradient used for the separation at 
0.7ml/min was linear from A 91.7% B 8.3% to B 27.7% at 24 min and then immediately B 
8.3% until 32 min. The day of the experiment the column was equilibrated with 50 column 
volumes of buffer A and at the end of the day the column was flushed with 10 volumes of 
water and 10 volumes of water:methanol 70:30.  
The peaks were analyzed using Mass Lynx spectrometry software (Waters). The amount of 
adenosine and pyridine nucleotides were calculated based on standard curve performed using 
adenosine nucleotides standard at concentration of 100mM.  
3.4 MITOCHONDRIAL INTERMEMBRANE POTENTIAL (ΔΨM) 
Mitochondrial intermembrane potential was measured in HDF and HDMEC using imaging 
plates and the same protocol as for the flux analysis. The media was replaced 1h before the 
measurement with XF media (see 2.3.1) and supplemented with 25nM TMRE (Molecular 
Probes). The measurements were performed with a LEICA SP5 II confocal microscope 
(Leica, Munich, Germany), equipped with heating plate station. Microscope settings: 
objective 40x, zoom x2, 4% laser power to avoid photobleaching and photodamage, 512x512 
pixel/image, λex/em 514-565/600, optimized Z stacks, and pinhole 1 Airy. Images were 
processed with image j software (rsb.info.nih.gov/ij). After identification of the mitochondria 
(“objects” with intensity >30), the total intensity from objects above 300 voxels was 
calculated and divided for the total objects area. Three fields for each sample were measured. 
The data represent three replicates of three individual experiments. 
For Δψm of mitochondrial network in proximity of primary cilia in IMCD3 (preliminary 
results), cells were seeded in Ibid 8 well chamber with glass bottom for live recording (Ibid, 
Martinsried, Germany), allowed to reach confluence and starved (see 2.1). The IMCD3 
Arl13b-TagRFP stable cell line was loaded with the potentiometric probe JC-1 (Molecular 
Probes) at final concentration of 8µM for 20 min. The medium was washed twice before the 
addition of new medium. Both JC-1 monomer (green) and aggregate (red) can be viewed 
using λ excitation at 488nm and emission at 505-535nm (green monomers) and 565-650nm 
(red aggregates).  The IMCD3 Arl13b-Venus stable cell line was loaded with 25nM TMRE in 
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the medium for 30 min prior the assays. Measurements were performed with a LEICA SP5 
confocal microscope, equipped with hybrid detectors. Microscope settings: objective 63x, 
512x512 and pinhole 1 Airy. Mitochondria as surface objects were localized using the surface 
tool of Imaris software (Bitplane, Zurich, Switzerland). Using the mean fluorescence per 
object and the volume of the object we calculated the mean fluorescence/voxel of all cellular 
mitochondrial network and the mitochondria within 2µM distance from each primary cilium. 
For JC-1 staining the calculation were done considering the red/green ratios for each object. 
Every image included at least 5-10 cells. 
3.5 CILIARY STAINING 
On 12mm diameter glass coverslips in 24 well plates, 2x104 IMCD3 or RPE1 cells were 
seeded and treated (see 2.1). The day of the experiment the cells were washed once in PBS 
and fixed using 3% paraformaldehyde (PFA) in PBS at 37° for 10 min. The PFA was 
removed and the cells washed 3 times in PBS. Fixed cells were permeabilized and the 
specific protein binding sites blocked using 5% FBS in PBS and 0,1% Triton for 30 min. 
After washing once, the cells were incubated overnight with primary antibodies against 
ciliary localized protein acetylated tubulin and ARL13b. The day after, cells were washed 3 
times in PBS and incubated with fluorescent secondary antibodies 1h in the dark at rT. After 
10 min incubation with PBS containing 1µg/ml DAPI the cells were washed twice and 
mounted on slides for imaging.  
LEICA SP5 II confocal microscope equipped with Hybrid detectors was used for imaging. 
Microscope settings: objective 63x, 512x512, sequential scan to avoid bleed through (DAPI 
λex/em 405 425-475, Green λex/em 488 505-535, Red λex/em 555 565-650), pinhole 1 Airy. 
Zoom, gain and laser power were dependent on the assays. For measurement of ciliary 
morphology in RPE1 cells Z stack were optimized. Cilia number was counted by visual 
recognition of both cilia and nuclei. Cilia morphology was measured using Imaris software as 
follows. After setting the threshold using the red channel (ARL13b), the objects recognized 
as cilia were analyzed singularly using the CC Bounding box tool, which identifies the 
maximum length for the long axis of the object.  
For ciliary staining in animal kidney slices see section 2.11.4. 
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3.6 MITOCHONDRIAL CONTENT 
3.6.1 Citrate Synthase  
HDF and HDMEC were harvested, washed once in PBS and suspended in 400µl (each 10cm 
plate) of buffer (Tris-HCl 10 mM, KCl 100 mM, KH2PO4 5mM, EGTA 1mM, EDTA 3mM, 
MgCl2 2mM, pH 7.4). Cells were counted with TC10 Automated Cell Counter (Bio-Rad, 
Hercules, U.S.) and stored in microfuge tubes at -20°C prior assay. Approximately 1-2x104 
cells were used for each measurement that was repeated in double for each sample. Three 
samples were measured at each experiment. 100µl of cell suspension was incubated in a 
quartz cuvette together with 740µl of Tris-HCl 125mM pH 8, 50µl Triton X-100, 3µl Acetyl-
CoA 30mM in water, and 50µl of 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) 2mM, under 
continuous stirring in SAFAS UVmc2 spectrophotometer (SAFAS S.A., Monaco) at 30°C 
for 3 min. The increase of absorbance at 412nM was measured for 2 min after addition of 
50µl freshly made 10mM oxaloacetate solution. Absorbance was then normalized for the cell 
count. 
3.6.2 mtDNA Copy Number and Tfam Gene Expression 
In HDF and HDMEC cells (Paper I), we measured the ratio between the mitochondrial genes 
CYTB and 16SrRNA and human nuclear genes GAPDH and RPL32 using qPCR (Applied 
Biosystems 7300 unit and ViA 7 Life Technologies). For min6m9 and IMCD3 cells 
(preliminary results) we measured the ratio between the mitochondrial genes Cox2 and 
16SrRNA and mouse nuclear genes Hbb and 18SrRNA. Briefly, cells were detached, washed 
in PBS, and suspended in 200µl PBS. Total DNA was extracted using QIamp DNA Blood 
Mini kit (QiAgen, Venlo, Netherlands) according to the manufacturer’s instructions and 
measured by NanoDrop 2000-C spectrophotometer (Thermo Scientific). PCR reactions 
consisted of 40 cycles using 4ng of total DNA template in a 20µL volume, containing 
SYBRGreen Supermix (Invitrogen) and 10pmol of each primer. 
Gene expression of Tfam was detected in IMCD3 and min6m9 cells (preliminary results) 
after mRNA extraction using TRIzol (Invitrogen). Briefly, 1 ml of reagent was added to 
every well of 12 well plate-containing cells. After 5 min the cells were detached and the 
suspension added in a microfuge tube containing 200µl of chloroform. The tubes were shaken 
for 15 sec and centrifuged 12000xg 10 min at 4°. The supernatant containing mRNA was 
pipetted in another tube containing 500µl isopropanol and left for 10 min at rT. The tubes 
were centrifuged again as before, the supernatant was discarded and 2 washes with 75% 
ethanol were performed. The pellet was suspended in 30µl deionized H2O and the quality and 
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quantity of mRNA was measured using NanoDrop. For each sample, 1 µg of mRNA was 
used to generate cDNA using Maxima First Strand cDNA synthesis kit (Invitrogen). qPCR 
reactions consisted of 40 cycles using 1µl of cDNA template in a 10µL volume, containing 
SYBRGreen Supermix (Invitrogen) and 10pmol of each primer. qPCR cycles were 
performed as follow: 15 sec of denaturation at 95°C and 30 sec of hybridization and 
extension step at 60°C.  
The primers were synthesized by Eurofins MWG Operon and are listed in Table 4. 
Primers Forward (5´-…-3´) Reverse (5´-…-3´) 
RPL32 TTAAGCGTAACTGGCGGAAAC GAGCGATCTCGGCAGAGTAA 
GAPDH ATGGGGAAGGTGAAGGTCG GGGGTCATTGATGGCAACATTA 
mtCYTB ACATCGGCATTATCCTCCTG GTGTGAGGGTGGGACTGTCT 
mt16sRNA GGCAGGTCAATTTCACTGGT AAATCTTACCCCGCCTGTTT 
Hbb AGGCAGAGGCAGGCAGAT GGCGGGAGGTTTGAGACA 
18s rRNA CGCGGT TCTATTTTGTTGGT AGTCGGCATCGTTTATGGTC 
mt12sRNA ACCGCG GTCATACGATTAAC CCCAGTTTGGGTCTTAGCTG 
mtCox2 AATTGCTCTCCCCTCTCTACG GTAGCTTCAGTATCATTGGTGC 
Tfam CAGGAGGCAAAGGATGATTC CCAAGACTTCATTTCATTGTCG 
Hmbs CGGAGTCATGTCCGGTAAC GGTGCCCACTCGAATCAC 
Tbp TGCTGTTGGTGATTGTTGGT CTGGCTTGTGTGGGAAAGAT 
Table 4. Primers used for gene expression and mtDNA measurements. 
3.7 CELL GROWTH 
3.7.1 Count 
HDF and HDMEC growth was primarily evaluated by cellular count using TC10 Cell 
Counter (Bio-Rad). Briefly, HDF (1,5-2,5x104) and HDMEC (6-8x104) were plated in 10cm 
Petri dish in triplicate, allow them to attach, and treated (see 2.1). After 3, 5 and 7 days the 
cells were harvested and counted. 
3.7.2 (6-3H)-Thymidine Incorporation 
HDF and HDMEC were plated (2x103 per well) in a 12 multiwell plate, allowed to adhere 
and treated. The third day, 3µCi of (6-3H)-thymidine (Perkin-Elmer) per well were added and 
the cells were incubated 4h. After washing twice with NaCl 0.9%, 750µl of 5% vol/vol 
trichloroacetic acid was added and the cells incubated 15 min at rT. The solution was then 
removed, 500µl of 0.1M NaOH were added and the plate slowly shaken for 2h. The solution 
was then transferred in scintillation tubes, and 4ml of Emulsifier-Scintillation Plus liquid 
(CiAB, Stockholm, Sweden) was added. The radioactive count was performed using Wallac 
1409 liquid scintillation counter (Perkin-Elmer).  
 36 
3.7.3 Cell Cycle Analysis 
IMCD3 and RPE1 cells were trypsinized, washed in PBS and fixed in a microfuge tube by 
slowly vortexing the cells in 500µl precooled (-20°)  ethanol 70%. After storage on ice for 1h, 
tubes were centrifuged 2 min at 4000 rpm. The pellet was suspended in 500µl PBS and 
returned 30 min on ice, followed by another centrifugation step. The pellet was suspended in 
300µl PBS containing 10µg/ml RNase A, 0,25% Triton X and 20µg/ml propidium iodide. 
The solutions were transferred in tubes and incubated in the dark for 15 min and then on ice 
prior measurements. The histograms analyzed using FLOWJO software (Ashland, U.S.) 
represent the fluorescence collected using PE-Texas Red filter from minimum 2x104 cells . 
The cell population used for analysis was identified using forward and side scatter and 
subsequent doublet discrimination (scatter width versus area).  Plotting the forward scatter 
versus the PE-Texas signal we analyzed the typical cell cycle distribution represented by two 
peaks (G1 and G2/M phases) and a valley (S phase). The analyzed peaks were reported as 
phase’s percentage of the total cells analyzed. 
3.8 MITOCHONDRIAL AND CYTOSOLIC REACTIVE OXYGEN SPECIES  
HDF and HDMEC were seeded in multiwell plates, allowed to reach confluence and treated. 
After 7 days, cells were washed once with PBS and loaded 1h in DMEM serum-free with 
10µM carboxy-methyl-2’-7’-dichlorofluorescin-diacetate (DCFDA, Molecular Probes). Cells 
were harvested, washed twice with PBS and fluorescence was detected by flow cytometry 
(Cyan, Beckman Coulter, Munich, Germany). Negative control was performed with 
unstained cells, whereas positive control was treated 30 min with tert-butyl hydroperoxide at 
final concentration of 100µM. 
In experiment using RPE1 and IMCD3 cells, DCFDA was loaded at final concentration of 
10µM for IMCD3 and 2,5µM for RPE1 in their corresponding culture medium. The cells 
were returned back into the incubator for 30 min than harvested, washed and suspended in 
500µl PBS. The measurement has been performed using BD FACSaria III (BD Biosciences).  
For all cell types mitochondrial ROS were measured using 2,5µM MitoSOX Red (Molecular 
Probes) loaded for 1h, followed by the same procedure described for DCFDA staining.  
3.9 APOPTOSIS  
To measure apoptosis in living cells we used Annexin V-FITC Apoptosis Detection Kit 
(Abcam, Cambridge, U.K.). IMCD3 cells were trypsinized, washed in medium and 
suspended in 500µl 1x binding buffer containing 5µl Annexin V FITC and 5µl PI (stock 
50µg/ml). The tubes were incubated 5 min in the dark and stored on ice prior the 
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measurements performed with BD FACSaria III. The population was identified as described 
above (see 2.7.3). Negative control was performed with unstained cells or either with 
Annexin V FITC or PI to set the gating. Positive control was performed using pro-apoptotic 
chemical staurosporin at final concentration of 6µM for 2h. In the resulting graph plotted 
with FITC versus PE-Texas red, we could identify a double negative population (living non-
apoptotic cells), a positive for Annexin V or PI (apoptotic and necrotic cells, respectively) 
and double positive population (apoptotic dead cells). The results in percentage were 
normalized on the total cells. 
3.10 WESTERN BLOT  
Cells were washed in PBS and for every 6cm dish 500µl of ice-cold RIPA modified lysis 
buffer (150mM NaCl, 50mM Tris-HCl, pH 7.4, 1% NP-40, 1mM EDTA and 0.1% DOC) 
supplemented with one unit of both Pierce phosphatase and protease inhibitor (Thermo 
Scientific) every 10 ml. For actin determination the lysis buffer used was 2% SDS in PBS to 
prevent repolymerization of actin filaments. The plates were scraped and left 15 min on ice. 
The suspension was transferred in a microfuge tube on ice and vortexed sometimes for 30 
min. The tubes were centrifuged at 4° 15 min 18000xg and the supernatant stored at -80° 
until usage. Protein measurement was performed using Lowry determination (140). 
After dilution with loading buffer and reducing agent the samples were boiled for 10 min to 
allow complete denaturation of the proteins. The samples were allowed to cool down before 
the loading in 10% polyacrylamide gel. All proteins were transferred in nitrocellulose 
membrane except WB involving actin (PVDF, GE Healthcare, UK). In gels used to 
determine actin and mTOR, the proteins were transferred using Bio-Rad wet transfer 
apparatus, while for the others we used semidry Trans-Blot Turbo apparatus (Bio-Rad). 
For actin determination the membranes were blocked 1h in PBS-Tween supplemented with 
5% milk powder and blotted using anti-β-actin and anti-γ-tubulin. The membranes were 
washed 4 times 10 min in PBST and incubated 1h with anti-mouse IgG horseradish 
peroxidase conjugate (GE Healthcare). After 3 washes the membranes were incubated 1 min 
with Supersignal West Femto chemiluminescent reagent (GE Healthcare). The membranes 
were scanned using LAS-1000 EMCCD camera (Fuji-film, Tokyo, Japan). 
For all other proteins, the membranes were blocked for 1h at rT using Odyssey blocking 
buffer (Li-Cor biosciences, Lincoln, U.S.). The membranes were washed 3 times 10 min in 
TBST and incubated overnight with the appropriate antibodies in Odyssey blocking buffer. 
The membranes were washed again and incubated 1h in the dark using fluorescent secondary 
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antibodies (Li-Cor). The membranes were washed again and developed using Odyssey 
imaging system (Li-Cor). The list of antibodies used is reported in Table 5. 
ANTIBODIES	 	 	 	 	 	 	 	
 SPECIES DILUTION COMPANY  SPECIES DILUTION COMPANY 
β-actin   Mouse 1:5000 Millipore Arl13b Rabbit 1:1000 Proteintech 
γ-tubulin  Mouse 1:5000 Sigma Tfam  Rabbit 1:2000 Abcam 
PDH-E1α 
(p293) 
Rabbit 1:1000 Millipore AMPKα Mouse 1:1000 Cell 
Signalling 
PDH-E1α 
(p300) 
Rabbit 1:1000 Millipore AMPKα 
pThr172 
Rabbit 1:1000 Cell 
Signalling 
PDHX Mouse 1:1000 Sigma AKT 
(pan) 
Mouse 1:1000 Cell 
Signalling 
Acetylated 
Tubulin 
Mouse 1:1000 Sigma AKT pSer 
473 
Rabbit 1:2000 Cell 
Signalling 
Aquaporin2 Mouse 1:500 Abcam Na+K+ 
ATPAse 
Mouse 1:500 Abcam 
IFT-88 Rabbit 1:1000 Proteintech mTOR Mouse 1:1000 Cell 
Signalling 
PRAS40 Rabbit 1:1000 Cell 
Signalling 
mTOR 
pSer 2448 
Rabbit 1:1000 Cell 
Signalling 
PRAS40 
(Thr246) 
Mouse 1:1000 R&D 
Systems 
    
IRDye 680LT 
anti-mouse 
Donkey 1:10000 Li-Cor IRDye 
680LT 
anti-rabbit 
Donkey 1:10000 Li-Cor 
Alexa 488 anti-
mouse 
Donkey 1:1000 Invitrogen Alexa 555 
anti-rabbit 
Donkey 1:1000 Invitrogen 
Table 5. Antibodies list. Primary antibodies are reported in bold. 
3.11 ANIMAL EXPERIMENTS 
3.11.1 Animal Model 
Animal experiments were conducted in female BKS.Cg-Dock7m+/+Leprdb/J (db/db) mice and 
their corresponding age-matched wild-type (wt) littermates (Charles River Laboratories, 
Wilmington, U.S.) at the age of 8 and 24 weeks. The manufacturer carried out the genotyping 
and body weight was determined immediately before sacrifice. Animal care and experiments 
were in accordance to the Animal Experiment Ethics Committee at Karolinska Institutet. 
3.11.2 Blood Measurements 
Non-fasting glucose, triglycerides and cholesterol were measured prior to euthanasia, using a 
drop of blood obtained from the vein tail. Blood glucose was determined using a FreeStyle 
Glucometer (Abbot Diabetes Care, Alameda, U.S.). Blood triglycerides and cholesterol levels 
were determined by using a multi-parameter diagnostic device for triglycerides and 
cholesterol (multiCare-in, Biochemical Systems International S.r.l., Arezzo, Italy). 
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3.11.3 Serum Biochemistry 
Biochemical studies were carried out in plasma samples in duplicate from five individual age-
matched animals. Before euthanasia, blood samples were collected from the vein tail in 
capillary tubes (Sarsted, Nümbrecht, Germany). Immediately after collection, blood samples 
were centrifuged at 4°C 5000xg for 30 min. After centrifugation, plasma was collected from 
the supernatant and transferred into two sets of tubes: one for creatinine determination and 
the others for hormonal characterization. Creatinine levels were measured in deproteinized 
plasma samples (10kDa spin columns to avoid interferences with the assay) by using a 
commercial colorimetric kit (Abcam). Plasma insulin, c-peptide, glucagon, adiponectin and 
leptin levels were measured in all animals using commercial ELISA kits (CrystalChem, 
Downers Grove, U.S. for insulin, glucagon, c-peptide and adiponectin; and Phoenix 
Pharmaceuticals Inc., Burlingame, U.S. for leptin).  
3.11.4 Histology and Immunohistochemistry 
For histological and immunohistochemical analysis, mice were anesthetized with isoflurane 
and transcardially perfused with PBS followed by freshly prepared 4% (wt/vol) PFA in PBS. 
Kidneys were dissected out and post-fixed for 2h in the fixative. Prior to cryopreservation 
kidneys were processed with a sucrose gradient (10-30% (wt/vol) sucrose solution in PBS 
containing 0.01% (wt/vol) sodium azide and 0.02% (wt/vol) bacitracin), frozen in dry ice and 
preserved at -80°C until use. 20µm sections were counterstained with hematoxylin-eosin for 
morphological studies. 
For immunohistochemistry, 20µm thick longitudinal kidney cryosections were collected on 
Superfrost Plus slides (Thermo Scientific). After sectioning, the slides were equilibrated at rT 
for 2h and then hydrated once for 5 min in PBS. Tissue permeabilization was performed for 
15 min using 0.5% (vol/vol) Triton X-100 in PBS. Thereafter, blocking solution containing 
5% (wt/vol) BSA and 0.5% (vol/vol) Triton X-100 in PBS was applied for 1h at rT before 
overnight incubation at 4°C with primary antibodies. Afterwards, sections were washed three 
times 5 min with 0.05% (vol/vol) Tween-20 in Tris/NaCl solution (0.1M Tris-Base; 0.15M 
NaCl). For double labeling appropriate secondary antibodies were applied 1h at rT. After 
incubation, sections were washed again three times 5 min and mounted using a mounting 
medium containing DAPI (ProLong® Gold Antifade, Thermo Scientific) for nuclear 
counterstaining. Images were captured using a Leica SP5 II confocal microscopy. Cilia 
number and length were measured per nuclei in the collecting duct and proximal tubule cells 
of kidney sections using two non-consecutive kidney sections separated by 200µm. For each 
 40 
section, 3 fields were collected in five individual animals per experimental group and controls 
at both ages. Cilia number and length were analyzed in double blind using ImageJ software. 
3.12 STATISTICAL ANALYSIS 
Statistical analyses were performed with Sigma Stat software (San Jose, U.S.) using t-test, 
Mann-Whitney or ANOVA and Tukey or Dunn post-hoc test after outliers identification and 
removal using Grubbs’ test (http://www.graphpad.com/quickcalcs/Grubbs1.cfm). Data are 
presented as mean ± s.e.m, median + IQr or mean + CI dependently of the data distribution 
and analyses applied, unless otherwise specified. Statistical significance was considered for p 
< 0.05. Data were represented graphically using Graph Pad Prism software (La Jolla, U.S.).  
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4 RESULTS AND DISCUSSION 
4.1  PAPER I. SHORT AND PROLONGED EXPOSURE TO HYPERGLYCEMIA 
IN HUMAN FIBROBLASTS AND ENDOTHELIAL CELLS: METABOLIC AND 
OSMOTIC EFFECTS 
Mitochondrial impairments during diabetes have been described in humans and animal 
models (see 1.2.5). However, the mechanisms linking mitochondrial impairments to diabetes 
complications still remain unclear. Mitochondrial metabolism and overproduction of ROS 
following hyperglycemia in vitro have been suggested to be the trigger for the activation of 
deleterious pathways involved in diabetes complications (31, 141-147). However, different 
mechanisms of cell damage in the absence of radicals have been found (148-150). In this 
paper, we aimed to clarify the metabolic response to acute and/or chronic hyperglycemia in 
human cells such as human primary dermal fibroblasts (HDF) and microvascular dermal 
endothelial cells (HDMEC), which are not insulin dependent for their glucose uptake and are 
involved in wound healing during diabetes.  
4.1.1 Mitochondrial and Metabolic Adaptations to Acute Hyperglycemia in 
Human Healthy Cells 
It has been suggested that raising extracellular glucose increases its uptake and utilization 
within cells expressing GLUT1 as main glucose transporter (31). Thus, we studied metabolic 
changes in HDF and HDMEC during acute hyperglycemia, using mannitol, which cannot 
penetrate the cell membrane, as osmotic control. In HDF, we measured the OCR using 
Seahorse Flux Analyzer (Fig.2A), where the cells were still adherent to the plate surface, as 
well as the oxygraph chamber (Paper I Fig.1E-H), in which the cells were floating after 
detachment. In good agreement with each other, both methods showed an acute decrease in 
Figure 2. Oxygen consumption rate (A) and extracellular acidification rate (B) normalized on the control (medium) in 
HDF after acute glucose (HG) or mannitol (M) treatments (black arrow). Black circle = glucose; open triangle = 
mannitol. Data are expressed by mean ± s.e.m. Significance was determined by ANOVA and Tukey post-test between 
[HG] vs [C] (*), [HG] vs [M] (†), and [C] vs [M] (#).  
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OCR compared to baseline respiration immediately after glucose addition. Moreover, we 
found a higher OCR in response to mannitol compared to glucose both in HDF (Fig.2A) and 
HDMEC (Paper I Fig.1C), although significantly reduced compared to the control. Along 
with decreased respiration after glucose addition, we found an increased ECAR indicating a 
metabolic switch towards aerobic glycolysis. These results were consistent in both HDF 
(Fig.2B) and HDMEC (Paper I Fig.1D) suggesting a common response to the acute 
hyperglycemic stress. 
To better clarify the cells response to hyperglycemia, we divided it into two components: 
osmotic stress (approximately from glucose addition to 120 min) and metabolic adaptation 
(from glucose addition onwards). The osmotic factor was proven by the fact that, after acute 
glucose or mannitol addition, the cells responded altering their metabolism until they resumed 
a new equilibrium. A previously described redistribution of molecules and ions during 
hyperosmosis might be the cause of these results (151, 152). Moreover, we suggest that the 
osmotic pressure could act mechanically on the mitochondria leading to a fast drop in 
oxidative phosphorylation. The metabolic component accounts for the difference in OCR and 
ECAR between glucose and mannitol treatments, which was still present when the new 
equilibrium after osmotic insult was established. The metabolic component of high glucose 
treatment was completely abolished by using an inhibitor of glucose uptake (cytochalasin B) 
(Paper I Fig.1I,L). In summary, the raise of extracellular glucose levels led to its intracellular 
utilization as fuel, reducing the OXPHOS and favoring the lactate production.  
In contrast with previous hypothesis (31) we found a reduced Δψm after acute exposure to 
glucose in HDF and HDMEC (Paper I Fig.3E,F). This event can be explained either by an 
increase in cellular respiration, a higher proton leak from the ETC, or due to alteration in the 
cell membrane potential (Δψp). Since our data demonstrated that glucose treatment induced a 
rapid decrease in respiration, and an acute boost of proton leak is unlikely in this short period 
of time, we suggest that the osmotic stress induced a re-equilibration of water content and ion 
charges into the cell pushing the probe outside the mitochondria thus decreasing the measured 
Δψm. In fact, it has been previously suggested that the osmotic insult could reversibly 
decrease the intracellular water content and increase in intracellular Ca2+ levels thus 
promoting mitochondrial depolarization (151, 152). The utilization at the same time of 
plasma membrane and Ca2+probes could serve as ultimate proof to clarify this result.  
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4.1.2 Hyperosmosis Reduces Cell Growth and Causes Cytoskeletal 
Rearrangement 
During acute hyperglycemia the body experiences short period of hyperosmosis before the 
kidneys establish a new osmotic equilibrium (152). Thus, metabolic changes associated to 
hyperosmosis during diabetes might be present as we observed in the metabolism of HDF 
and HDMEC. Together with metabolic alterations during hyperosmosis, we also found a 
reduced cell proliferation in both HDF (Fig.3A,C and Paper I Sup.Fig.1H) and HDMEC 
(Fig.3B and Paper I Sup.Fig.1H). We found that cell growth during hyperglycemia was 
comparable to the one using mannitol and was dependent on their concentration in the 
medium (Paper I Sup.Fig.2A). Moreover, cells exposed to hyperglycemia as well as 
mannitol, displayed an increase in protein content (Paper I Fig.5D and Sup.Fig.2B), which 
was, at least in part, due to the raise in β-actin protein levels (Paper I Fig.5E,F).   
In our view, the re-organization of the cytoskeleton to counteract the osmotic pressure was 
the main reason for the reduced cell proliferation. The decreased cell growth due to 
hyperosmosis as component of high glucose, can partly provide an in vitro explanation for 
some in vivo complications of diabetes involving fibroblasts and endothelial cells, such as the 
reduced wound healing ability in diabetic patients (153). 
4.1.3 Prolonged High Glucose Exposure Reset Metabolism with Changes in 
Cellular Energy Levels 
Prolonged exposure to high glucose has been demonstrated to activate deleterious pathways 
leading to diabetes complications. Under condition of chronic hyperglycemia, diabetic tissues 
seem to exhibit decreased energy levels and higher oxidative stress (see 1.2.5 and 1.2.6). 
Therefore, we aimed to better understand the impact of chronic hyperglycemia on 
mitochondrial function and energy metabolism. Thus, we mimicked in vitro a condition of 
Figure 3. A-B) Cellular growth of HDF (A) and HDMEC (B). Regression curve mean + CI. C = control HG = high 
glucose. C) Thymidine incorporation at day 3 in HDF treated with glucose (black bar), mannitol (squared bar), and control 
cells (white bar). Data are expressed by mean ± s.e.m. Significance was determined by ANOVA and Tukey post-test 
between [HG] and [M] vs [C].  
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long-term exposure to high glucose levels culturing confluent HDF and HDMEC and 
measured mitochondrial and cellular bioenergetic parameters. Also here, we used mannitol as 
osmotic control. After 7 days of treatments, we found that high glucose culture shifted the 
fuel utilization from mitochondrial OXPHOS to aerobic glycolysis (Paper I Fig.2E). This 
result is in line with the one described above during the acute hyperglycemic treatment 
(Fig.1). In fact, the basal OCR was decreased in both HDF and HDMEC (Fig.4), while the 
ECAR and thus lactate production increased (Paper I Fig.2D). Moreover, the uncoupled 
mitochondrial respiration was slightly but significantly reduced after one week of high 
glucose exposure (Fig.4). The reason of this metabolic switch remains elusive. It might be 
speculated that a less effective ATP production to clear the intracellular glucose favors lactate 
production to be able to re-oxidize the coenzyme NADH necessary to avoid the slowdown of 
glycolytic flux.  
Cells exposed to chronic hyperglycemia were able to maintain high ATP levels even though 
the aerobic glycolysis is less efficient. However, the raise in ADP in cells treated with high 
glucose changed the ATP/ADP ratio (Paper I Fig.4A,B). The cause of this imbalance could 
be attributable, as mentioned above, to an increase in energy expenditure for protein synthesis 
during high glucose treatment. An alternative explanation could be the usage of ATP to 
maintain the Δψm using the ATPase in a reverse mode. However, adenosine nucleotides ratio 
is different between cytosol and mitochondria and, with the techniques in our knowledge, we 
could not discern in which compartment the ATP/ADP ratio was changed.  
Figure 4. A-B) OCR after one week of high glucose or mannitol exposure in HDF (A) and HDMEC (B). Data are 
expressed by mean + CI. Significance was determined by ANOVA and Tukey analysis between high glucose [HG] vs 
control [C] (*), and [HG] vs mannitol [M] (†). 
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The decrease in respiration and the preference of aerobic glycolysis we observed after 
prolonged exposure to hyperglycemia was not due to ROS overproduction, which could 
affect the ETC functions (Paper I Fig.3I,L). The absence of ROS during hyperglycemia was 
corroborated by the absence of changes in cellular redox state by means of NAD+/NADH 
ratio (Paper I Fig.4A,B). However, as for the ATP/ADP ratio, the total NAD+/NADH ratio 
does not consider the compartmentalization between cytosol and mitochondria.  
The decrease in OCR we found after long-term exposure to hyperglycemia was not due to an 
impairment of ETC activity (Paper I Fig.3M) suggesting a metabolic regulation of fuel 
channeling from pyruvate to lactate bypassing the mitochondrial respiration. One possible 
candidate diverting the pyruvate away from mitochondrial utilization is the enzyme pyruvate 
dehydrogenase (PDH). Even though we did not detect difference in its phosphorylation state 
(Paper I Fig.2C and Sup.Fig.1D,E), a decrease in Ca2+ levels as adaptive mechanism to 
counteract hyperglycemia could be a factor inactivating the enzyme without changes in 
phosphorylation state (154).   
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4.2 PAPER II. PRECONDITIONING WITH ASSOCIATED BLOCKING OF CA2+ 
INFLOW ALLEVIATES HYPOXIA-INDUCED DAMAGE TO PANCREATIC 
BETA-CELLS 
PAPER III. HYPEROXIA INHIBITS GLUCOSE-INDUCED INSULIN 
SECRETION AND MITOCHONDRIAL METABOLISM IN RAT PANCREATIC 
ISLETS  
Transplantation of pancreatic islets is used as rescue treatment for insulin-dependent diabetic 
patients. During islets engraftment, the hypoxic environment preceding islets 
neovascularization leads to the loss up to more than half of the transplanted islets (155). To 
improve the yield and function of the transplanted islets, several approaches are currently 
being developed (see 1.1.6). In papers II and III, we explored possible pre-hypoxia and/or 
pre-transplantation treatments of pancreatic islets using either the K+ATP channel opener 
diazoxide or high oxygen tension (hyperoxia) to reduce the negative impact of hypoxia 
during engraftment. Moreover, we studied how hypoxia as well as hyperoxia affect 
mitochondria, metabolism and secretion of pancreatic islets in vitro. 
4.2.1 Hypoxia and Hyperoxia Impair Insulin Secretion and Mitochondria of 
Pancreatic Islets  
In paper II, we used islets of Langerhans isolated from rats and cultured them for 5.5 hours at 
0.8% oxygen tension (hypoxia). We found that hypoxia induced a significant reduction in the 
biosynthesis of insulin and proinsulin (Paper II Fig.4A and Sup.Fig.1A), together with a 
lower rate of insulin secretion upon glucose stimulation and total insulin content (Paper II 
Fig.3A,B). Insulin biosynthesis and release are ATP dependent and rely on mitochondrial 
energy production, since lactate production is negligible in β-cells (8). Therefore, we 
investigated the effect of hypoxia on islets mitochondria and found that the decrease in 
insulin secretion and production was accompanied by a reduction in number of mitochondria 
and ETC complexes I, II and III (Paper II Table 1 and Fig.5).  
Same parameters were measured again after re-oxygenation of the islets to mimic the 
recovery phase after the hypoxic insult during islets engraftment in vivo. Here, we found that 
after 22 hours of re-oxygenation, the cells within the islets were not able to completely restore 
their previous metabolic functions (Paper II Fig.6D,E). However, we found some 
improvements in several metabolic and mitochondrial parameters such as insulin and 
proinsulin content, insulin secretion, mtDNA, ETC complexes and ATP levels.  
The decrease in mtDNA and ETC complexes after hypoxia re-oxygenation was in line with 
the marked decrease in basal and glucose-stimulated islets OCR (Fig.7). However, the 
absolute respiratory response to glucose stimulation was maintained, confirming that the 
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defective insulin secretion observed in pancreatic islets subjected to hypoxia was due to a 
decrease in mitochondrial number or ETC complexes rather than an impairment of the ETC 
itself. In line with our finding, previous works showed that mitochondrial mass and gene 
expression were reduced during hypoxia, which could be due to cellular energy depletion 
(156, 157). This effect can be more relevant in β-cells, where the glycolysis alone cannot 
compensate for the cellular ATP needs. Other possible explanation for the decreased 
respiration in pancreatic islets after hypoxia re-oxygenation treatment could be the reduction 
in β-cells mass due to necrosis (Paper II Fig.4D). The mechanisms causing mitochondrial 
dysfunction during hypoxia are still not clear. The reasons could be the high ATP levels 
necessary for the function of mtRNA polymerase (156), mechanisms to save cellular energy 
such as proteolysis, or ROS overproduction (158). In contrast, other works found an 
upregulation of mitochondria biogenesis in response to hypoxia (159, 160). However, the 
level of oxygen required for cells to be hypoxic depends on the metabolism of the specific 
tissue since the respiratory gradient (which depends on the mitochondrial respiration) 
determines the access of oxygen into the cells (158). Moreover, the time of hypoxic exposure 
and the accountability for ATP production by OXPHOS for each cell and tissue is a 
determinant of cell fate during hypoxia. 
Whereas hypoxia is deleterious after transplantation, hyperbaric management was found to 
improve functionality and yield of transplanted islets due to a decrease in apoptosis (155). An 
intriguing perspective would be to culture isolated islets in a hyperoxic environment for a 
limited period of time to possibly upregulate mechanisms to endure the initial hypoxia after 
transplantation. Thus, in paper III we investigated this possibility culturing the islets for 18 
hours at 95% oxygen tension. We found that hyperoxia decreased glucose-induced insulin 
secretion (Paper III Fig.2A) without reducing insulin content (Paper III Fig.2B). Necrosis or 
apoptosis after the hyperoxic period was not detected (see Paper III section 3.5). These results 
led us to investigate whether the defective insulin secretion observed under hyperoxic 
conditions could be related to a disrupted mitochondrial metabolism. Indeed, we found a 
decrease in mitochondrial respiration both at basal level and after glucose stimulation (Fig.5 
and Paper III Fig.2E), together with a reduction in the protein levels of mitochondrial 
complexes I and II (Paper III Fig.2F). 
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Although hyperoxia was found 
previously to induce oxidative stress, we 
detected a decrease in cytoplasmic ROS 
and an significant increase only after 
further 22h normoxic culture (see Paper 
III section 3.4) (158). This result might 
be due to the difference in tissues 
metabolism or time of treatments we 
used compared to previous works. 
Finally, we cultured the islets 5.5 hours in 
hypoxia after hyperoxia and did not find a 
protection induced by hyperoxic treatment (Paper III Fig.4).  
4.2.2 Diazoxide Protects Islets from Hypoxia and Increase Yield after 
Transplantation 
In paper II, we aimed to test pharmacological approaches to ameliorate the negative effects of 
hypoxia. Here we used the K+ATP  channel opener diazoxide to pretreat pancreatic islets for 22 
hours prior to hypoxic culture or transplantation. This chemical was chosen due to its 
protective effect against hypoxia in excitable cells such as nerve and myocardium (161). Rat 
pancreatic islets pretreated with diazoxide improved insulin secretion and insulin content 
(Fig.6 and Paper II Fig.4A). Using the same protocol, we could reproduce the increase in 
insulin content in human islets 
(Paper II Pag.8). The positive 
effect of diazoxide on insulin 
content and secretion had been 
recently corroborated using a 
model of cold ischemic pancreatic 
tissue perfused with this 
compound. Isolated islets from 
ischemic and diazoxide treated 
mice, displayed preserved 
mitochondrial morphology and 
network (162, 163). Moreover, 
cell necrosis in rat islets observed 
during the re-oxygenation phase 
was partially decreased by diazoxide pretreatment (Paper II Fig.4D). Whereas hypoxia 
Figure 6. Insulin secretion at basal level (3.3mM glucose) and following 
glucose stimulation (16.7mM glucose) after different treatments. Data 
are expressed as mean ± s.e.m. Significance was calculated using t-test 
or Anova and Student-Newman-Keuls. Before re-oxygenation: * 
hypoxia vs normoxia. P<0.02. After re-oxygenation: † hypoxia vs no 
re-oxygenation P<0.01, ++hypoxia re-oxygenation vs normoxia re-
oxygenation P<0.02 § diazoxide pretreatment vs no diazoxide P=0.027. 
Figure 5. OCR of rat islets cultured at 95% oxygen tension (red 
circles) and normoxia (blue circles). Injections: A glucose; B 
Oligomycin; C FCCP; D antimycin. Data are expressed as mean 
± s.e.m..  
 
 49 
decreased significantly mitochondrial complexes I, II and III, in diazoxide preconditioned 
islets the levels were comparable to control (Paper II Fig.5). After re-oxygenation, islets 
cultured in hypoxia (diazoxide pretreated or not) displayed similar amount of mitochondrial 
complexes compared to control, with the exception of complex I in hypoxia treated islets 
(Paper II Fig.5).  
In contrast, we found a reduction of the amount of mtDNA after hypoxia/re-oxygenation 
compared to normoxic culture (Paper II Table 1). The decreased mtDNA content after 
hypoxic culture, and thus probably the number of mitochondria, was in line with the decrease 
of both basal and glucose-stimulated respiratory levels (Fig.7). Moreover, ATP levels, protein 
content and glucose oxidation were markedly decreased after hypoxia (Paper II Table 1).  
We suggested that the opening of K+ATP channels and the consequent blockade of Ca2+ inflow 
into the β-cells were able to keep the islets in a “resting state” protecting them from hypoxia. 
This concept was introduced before by Ritzel and colleagues, using a selective K+ATP channel 
opener in β-cells (164).  
Thus, we used the Ca2+ channel blocker nifedipine or a co-treatment with the K+ATP channel 
closer tolbutamide and diazoxide. Here, the positive effect of diazoxide was blocked by 
tolbutamide, while nifedipine had similar effect compared to diazoxide, strongly suggesting 
that blockade of Ca2+ inflow in β-cells was protective from hypoxia (Paper II Fig.7A,B). 
Corroborating our hypothesis, diazoxide as well as nifedipine preconditioning decreased 
glucose oxidation even in presence of normal oxygen tension (Fig.8).  
Figure 7. A) OCR of rat islets after treatment with hypoxia and re-oxygenation 
and/or treatment with diazoxide measured using Seahorse Flux Analyzer. B) 
Summary of basal (3.3 mmol/l glucose) and glucose-stimulated (16.7 mmol/l 
glucose) islets OCR. C) OCR normalized to basal levels. Data are expressed 
as mean ± s.e.m.. Significance was calculated using Anova and Student-
Newman-Keuls. *P<0.05 vs no previous hypoxia. 
 
A B 
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An alternative mechanism of decreased necrosis after re-oxygenation could be a reduction in 
ROS, which can be mediated by the uncoupling effect of diazoxide. Further, it has been 
suggested that diazoxide effect could be due to the transient opening of the mitochondrial 
transition pore during preconditioning, which might protect the cells from ischemia-
reperfusion (165). 
After we found a protective effect of diazoxide from hypoxia re-oxygenation in vitro, we 
sought to demonstrate its efficacy after transplantation. Thus, we measured the insulin 
content in engrafted islets 5 days after transplantation in non-diabetic rats. In preconditioned 
islets we found increased insulin content as well as cell survival compared to the absence of 
treatment (Paper II Fig.8). Moreover, preconditioned rat or human islets were more effective 
to lower blood glucose levels when transplanted in streptozotocin treated mice (Paper II 
Fig.8B-D). These results provide new therapeutic values for K+ATP channel openers to 
improve the efficacy and the efficiency of the islet transplantation.   
Figure 8. Diazoxide (A) or Nifedipine (B) effect on glucose oxidation in pancreatic islets. Data are expressed as mean ± 
s.e.m.. Significance was calculated using t-test. * P<0.05 vs. no preconditioning. 
 
A B 
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4.3 PAPER IV. CILIARY/ BASAL BODY DYSFUNCTION IMPAIRS INSULIN 
SECRETION SIMILAR TO THAT IN TYPE 2 DIABETES SUSCEPTIBILITY  
The primary cilium is an organelle involved in multiple cellular signaling pathways and tissue 
homeostasis (108). Although the importance of ciliary signaling is well recognized during 
development, the impact of cilia in tissue homeostasis is still largely unexplored. Recently, 
ciliary function has been involved in mTOR signaling (113-115) and autophagy (116, 117). 
Features of two different ciliopathies, namely BBS and Alström disease, are obesity and high 
comorbidity with diabetes, providing a possible link between insulin signaling and primary 
cilia. In this work we investigated this link and its possible mechanism of action. 
4.3.1 Ciliary Dysfunctions Impair Insulin Secretion and Promote 
Development of Type 2 Diabetes in Rodents 
To study the link between primary cilia and diabetes we first used a ciliopathy mouse model 
of BBS (Bbs4-/- mouse), which develops obesity and diabetes. Although the islets and 
pancreas developed normally without differences in insulin content, at 7-9 weeks of age the 
mutants displayed impaired glucose tolerance compared to wild type mice (Fig.9A).  
We cannot exclude that at this stage a different distribution of lean and fat mass could play a 
role in this phenotype. In fact, pair-weight mice and human subjects affected by BBS display 
increased abdominal adiposity (166, 167). To test whether defects in ciliary/basal body can 
impair insulin secretion, we used shRNA targeting two basal body proteins in isolated islets 
and min6m9 cells, namely Oral-facial-digital syndrome I (OFD1) and Bardet-Biedl-
Syndrome 4 (BBS4). We found a reduced first-phase insulin secretion in treated islets 
(Fig.9B), which was rescued by overexpression of human BBS4 in Bbs4 shRNA knock down 
islets (Paper IV Fig.2B). We excluded a metabolic defect in min6m9 cells due to the cilium 
impairment by measuring glucose-stimulated mitochondrial respiration and glucose uptake 
Figure 9. A) Glucose tolerance of Bbs4-/- mice compared to wild type littermate. Data are expressed as mean ± s.e.m.. 
Significance was calculated using t-test. P=0.0496. B) Glucose-stimulated insulin secretion of whole islets depleted of 
Ofd1 or Bbs4 mRNA. Data are expressed as mean ± s.e.m.. Significance was calculated using ANOVA. *P=0.001. 
A B 
 52 
(Fig.10A,B respectively). Moreover, we excluded defective microtubular organization defects 
in Bbs4 and Ofd1 depleted cells (Paper IV Fig.3B-E), which has been previously suggested 
regarding BBS protein (168).  
 
 
 
 
 
 
 
Due to the similar phenotype between Bbs4-/- and βIRKO mice (insulin receptor knockout in 
β-cells (169)), we investigated the possible interaction between insulin receptor and primary 
cilium. Interestingly, we found that only activated insulin receptor A (IR-A) isoform, but not 
IR-B, was recruited to the cilium in min6m9 cells and human β-cells upon insulin stimulation 
(Paper IV Fig.4). In Bbs4 and Ofd1 depleted cells we found reduced insulin content after 
glucose challenge (Paper IV Fig.5J), which could be due to the reported activity of IR-A to 
activate transcription of insulin (ins) (170)). The necessary recruitment of IR to the cilium for 
insulin signal transduction was showed by the reduced phosphorylation of protein kinase B 
(AKT) and regulatory subunits of phosphatidylinositol-3-kinase (PI3K) (Paper IV Fig.5A-F) 
in both min6m9 cells and islets depleted of Bbs4 and Ofd1. AKT is upstream activator of 
Forkhead Box Protein O1 (FOXO1), which in turn regulates Syntaxin1a protein (STX1a). 
STX1a is in turn implicated in the soluble N-ethylmaleimide attachment receptor (SNARE) 
complex necessary for insulin exocytosis.  We found a reduction in mRNA and protein levels 
of STX1a and SNAP25 components of the SNARE complex in islets treated with Bbs4 and 
Ofd1 shRNA as well as in islets from Bbs4-/- mice (Paper IV Fig.5G,H). Furthermore, 
overexpression of STX1a in min6m9 cells increased the insulin disposition index similar to 
control (Paper IV Fig.5I). These results confirmed that the disrupted insulin signaling we 
described above in Bbs4 and Ofd1 knock down islets as well as in isolated islets from Bbs4-/- 
mice, could be the cause of impaired exocytosis machinery.  
Finally, we established a link between primary cilium and diabetes. Here, we found a strong 
reduction of ciliated cell per area in the lean model of diabetes Goto-Kakizaki rats (GK), 
Figure 10. A) OCR of min6m9 cells depleted of Ofd1 
and Bbs4 after glucose stimulation. Data are 
expressed as mean ± s.e.m.. B) Glucose uptake 
normalized on control in min6m9 cells depleted of 
Ofd1 and Bbs4. Data are expressed as mean + IQr and 
range. 
B A 
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when β-cells density and islet volume are still conserved (2-3 months of age) but 
hyperglycemia is present (Paper IV Fig.6A-G). In the same rats, we found a dysregulation of 
ciliary genes (Ift88, Bbs4, Pmc1), increased protein levels of PMC1 and KIF3a and decreased 
levels of STX1a (Paper IV Fig.6H,I).   
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4.4 PRELIMINARY RESULTS I: ENERGY BALANCE AND REACTIVE OXYGEN 
SPECIES AFFECT PRIMARY CILIUM MORPHOLOGY 
In addition to other signaling pathways previously linked to the primary cilium (see 1.3), we 
found that this organelle is also involved in the insulin signaling in β-cells (see 4.3). Cilia 
formation, maintenance and function are energetically costly and highly dependent on ATP, 
which is mainly (80-90% depending on cell type) produced by mitochondrial OXPHOS (171, 
172). In this work, we aimed to elucidate how mitochondrial function and thus cellular 
energy balance influence ciliary maintenance. Here, we report cilia morphology changes in 
response to energy depletion as well as mitochondrial ROS production. Moreover, we 
translated our in vitro results into in vivo evidence of defective ciliogenesis in kidney of a 
diabetic mice model.  
4.4.1 Blocking Complex I or ATPase Decrease Energy Levels and Ciliation in 
IMCD3 
To investigate the link between mitochondrial function and ciliary homeostasis we treated 
mouse inner medullary collecting duct cells (IMCD3) with increasing concentrations of 
rotenone, an inhibitor of mitochondrial complex I (Fig.11A,B). After 48h, blockade of 
complex I decreased the number of ciliated cells in a dose-dependent manner (Fig.11B) 
Figure 11. A) Representative image of IMCD3 cell line control (top panel) and treated with 100nM of rotenone (bottom 
panel) for 48h. Cilia stained with anti-acetylated tubulin are indicated with white arrows. B) Quantification of dose-
dependent effect of rotenone on number of ciliated IMCD3 cells. Data represent 3 experiments (n=16 with approximately 
20 cells each). Median + IQr, Kruskal-Wallis + Dunn´s P=0.001. C) ATP and ADP cell content normalized on the control 
in IMCD3 treated 48h with 25nM rotenone or 50nM oligomycin. Data represent 3 experiments (n>5). Median + IQr, 
Kruskal-Wallis + Dunn´s. P=0.001. D) ATP/ADP ratio in IMCD3 treated as above. Data represent 3 experiments (n>5). 
Mean + s.e.m ANOVA + Tukey. P<0.001. E) Quantification of IMCD3 ciliated cells treated as above. Data represent 4 
experiments in duplicate (n>15 with approximately 60 cells/field). Mean + s.e.m ANOVA + Tukey. P<0.001. F) 
Representative WB and quantification of IFT88 protein in IMCD3 treated as above. Data represent 4 experiments (n>7). 
Mean + s.e.m ANOVA + Tukey. P<0.001.  
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(ciliated cells % normalized to the control; median + IQr: control 1.00 (0.84, 1.19); rotenone 
25nM 0.71 (0.36, 0.97); 50nM 0.68 (0.31, 0.92); 100nM 0.32 (0.18, 0.60)). Using a second 
batch of cells we further tested whether the decrease of ciliation was related to the cell energy 
status or to a rotenone specific effect. Thus, we used oligomycin to decrease the 
mitochondrial ATP output and, at the same time, measured cilia number and cell energy 
status by means of nucleotides content. Here, we found that 48h treatments with either 25nM 
rotenone or 50nM oligomycin were able to decrease the total energy status (Fig.11C) and the 
ATP/ADP ratio (Fig.11D) in a similar extent (nmoles ATP/mg protein normalized on the 
control; median + IQr: control 1.00 (0.98, 1.08); rotenone 0.43 (0.14, 0.72); oligomycin 0.45 
(0.18, 0.85)) (ATP/ADP ratio normalized on control; mean ± s.e.m. control 1.00 ± 0.03; 
rotenone 0.46 ± 0.08; oligomycin 0.51 ± 0.05). Interestingly, not only rotenone, but also 
oligomycin treatment was able to reduce the amount of ciliated cells compared to the control 
(Fig.11E) (ciliated cells normalized to the control; mean ± s.e.m.: control 1.00 ± 0.03; 
rotenone 0.58 ± 0.05; oligomycin 0.78 ± 0.05). To corroborate the finding of impaired 
ciliogenesis, we measured the intraflagellar transport protein 88 (IFT88) as part of ciliary 
transport mechanism and found reduced protein levels comparable with the decrease in 
ciliation after treatment with rotenone and oligomycin (Fig.11F) (Ift88/γtub normalized on 
control; mean ± s.e.m.: control 1.00 ± 0.03; rotenone 0.61 ± 0.05; oligomycin 0.81 ± 0.05).  
Our results suggest that reducing the ATP content in IMCD3 cells impairs ciliogenesis. The 
effect of reduction in cellular energy could decrease the activities of ATP-dependent motor 
proteins such as kinesin and dynein and Rheb and Ras GTPases involved in transport and 
import of ciliary proteins (125-127). However, rotenone had a stronger effect on reducing 
ciliated cells compared to oligomycin treatment suggesting an additive mechanism to impair 
ciliogenesis other than decrease in cellular energy status.  
4.4.2 Reactive Oxygen Species, but not Cell Cycle and Apoptosis, are in part 
Responsible for Decreased Ciliation in IMCD3 
As well known, rotenone binding to the complex I causes overproduction of superoxide anion 
thus increasing intramitochondrial ROS (96). However, depending on the metabolic state of 
the cell, also oligomycin can induce ROS formation by blocking the respiratory chain in a 
similar state 4 (90, 109). We therefore investigated rotenone and oligomycin induced ROS 
production as a possible effector of the decreased ciliogenesis.  
Rotenone, but not oligomycin, increased the intramitochondrial ROS (Fig.12A and 
Sup.Fig.1A) (MitoSOX Red intensity normalized to the control; median + IQr: control 1.00 
(0.94, 1.06); rotenone 1.95 (1.62, 3.00); oligomycin 1.02 (0.86, 1.34)). ROS production by 
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rotenone resulted also in an increase of cytosolic radicals (Fig.12B and Sup.Fig.1B). 
Moreover, oligomycin treatment was also responsible for an increase in cytosolic ROS 
similar to the one in presence of rotenone (Fig.12B) (DCFDA intensity normalized on 
control; median + IQr: control 1.00 (0.93, 1.07); rotenone 4.28 (3.07, 6.22); oligomycin 3.20 
(2.60, 7.64)).  
To reproduce the cytosolic redox imbalance using another approach and investigate cilia 
morphology, we treated the cells with the oxidative stress inducing agent tert-butyl 
hydroperoxide (TBOOH) for 48h. In this case the number of ciliated cells was unaffected 
using concentrations up to the point in which the compound induced cell death (100µM) 
(Sup.Fig.1C). However, at all concentrations TBOOH did not reproduce the redox imbalance 
we found using mitochondrial inhibitors (Sup.Fig.1D). Using a different radical inducer such 
as paraquat, we replicated the same results (Sup.Fig.1E). As evidence that ROS are involved 
in decreased cell ciliation, we then adopted the opposite approach by quenching the radicals 
induced by rotenone with a combination of hydrosoluble (ascorbic acid and Tiron) or a 
liposoluble (retinoic acid) antioxidants. By administration of these compounds in 
combination with rotenone for 48h (Fig.12C), we found a significant maintenance of ciliated 
cells compared to rotenone alone (ciliated cells % normalized on the control; mean ± s.e.m.: 
control 1.00 ± 0.03; rotenone 25nM 0.53 ± 0.04; rotenone + tiron and ascorbic acid 
0.77±0.03; rotenone + retinoic acid 0.72 ± 0.03). However, this approach was not able to 
completely restore the cilia at the level of the control cells. These results showed that ROS 
Figure 12. A) Quantification of MitoSOX intensity in IMCD3 cells treated 48h with 25nM rotenone or 50nM 
oligomycin. Data represent 6 experiments (n>11 of 50000 events). Median + IQr, Kruskal-Wallis + Dunn´s. P<0.001. B) 
Quantification of DCFDA intensity in IMCD3 cells treated as above. Data represent 5 experiments (n=10 of 50000 
events). Median + IQr, Kruskal-Wallis + Tukey. P<0.001. C) Quantification of cilia number in IMCD3 cells treated 48h 
with 25nM of rotenone in the presence of antioxidants (Tiron + Vit.C 1mM, retinoic acid 1uM). Data represent 4 
experiments (n>16) Mean + s.e.m ANOVA + Tukey. P<0.001. 
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have an impact on cilia loss in IMCD3, which was at least partially restored by using 
antioxidants. The different reduction of ciliated cells after rotenone and oligomycin 
treatments, in the presence of an equally reduced energy status, could be simply due to the 
timing of the radical production and exposure to the chemicals. However, we cannot exclude 
that ROS generated at specific sites could act through a different signaling pathway compared 
to the ones generated outside mitochondrial matrix. 
We next investigated whether impairments in the cell cycle could be a possible cause of 
decreased ciliation in IMCD3 (Fig.13A). Here, we found a significant increase in the S phase 
after rotenone treatment and a decreased G1 phase in cells treated with rotenone and 
oligomycin (S phase; mean ± s.e.m.: control 17.2 ± 1.5; rotenone 27.0 ± 3.3; oligomycin 22.6 
Figure 13. A) Cell cycle analysis with PI staining in IMCD3 treated for 48h with 25nM rotenone or 50nM oligomycin. 
Representative image of cell cycle plot in control cells. Data represent 4 experiments (n>8 with 50000 events each). G0-1 
phase: median + IQr, Kruskal-Wallis + Tukey. P<0.001. S phase: mean + s.e.m, ANOVA + Tukey. P=0.043. G2M phase: 
mean + s.e.m, ANOVA. P=0.94 B) Representative image of WB of phosphorylated and total mTOR in IMCD3 treated as 
above. C) Quantification of B) p-mTOR/mTOR. Data represent 4 experiments (n>7). Median + IQr, Kruskal-Wallis + 
Dunn´s. P<0.001 D) Quantification of B) p-mTOR and mTOR normalized on loading control. Data represent 4 
experiments (n>7). pmTOR/γtub: mean + s.e.m, ANOVA + Tukey. P=0.003. mTor/γtub: median + IQr, Kruskal-Wallis. 
P=0.37. E) Representative image of WB of phosphorylated and total PRAS40 in IMCD3 treated as above. F) 
Quantification of E) p-PRAS40 and PRAS40 normalized on the loading control. Data represent 3 experiments (n>6). 
Mean + s.e.m ANOVA + Tukey. pPRAS40/γtub P=0.006. Pras40/γtub P<0.001 G) Representative image of WB of 
phosphorylated and total AMPKα in IMCD3 treated as above. H) Quantification of G) p-AMPKα versus AMPKα. Data 
represent 3 experiments (minimum n=6). Median + IQr, Kruskal-Wallis + Tukey. P=0.003. I) Quantification of G) 
AMPKα vs loading control. Data represent 3 experiments (n>6). Mean + s.e.m ANOVA + Tukey. P=0.002 J) Analysis 
of apoptotic and necrotic IMCD3 treated as above normalized per 100 events. Representative image of control cells plot. 
Staurosporin 6µM has been added 2h prior the trypsinization as positive control. Data represent 4 experiments (n=9 with 
20000 events each). Live: Mean + s.e.m, ANOVA + Tukey P<0.001. Apoptotic: median + IQr, Kruskal-Wallis P=0.59. 
Dead: median + IQr, Kruskal-Wallis P=0.88. Apoptotic + Dead: median + IQr, Kruskal-Wallis + Tukey P=0.012.  
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± 2.6) (G0-1 phase; median + IQr: control 100.0 (98.7, 101.2); rotenone 89.1 (82.9, 93.9); 
oligomycin 94.1 (92.6, 96.7)). None of the treatments significantly affects the G2M phase. 
One of the main regulators of cell cycle is the mTOR pathway, which has also been linked to 
primary cilium. On one hand a reduced ciliation using knock down approaches resulted in 
mTOR hyperactivation (114, 117, 173). On the other hand, inhibition of mTORC1 has been 
shown capable to regulate ciliary length via decreased protein synthesis (174, 175). Here, we 
found a decreased mTOR phosphorylation in cells treated with rotenone and oligomycin, 
which was in accordance with cell cycle analysis (Fig.13B,C). Decrease in absolute mTOR 
phosphorylation was significant after rotenone treatment (Fig.13B,D), without changes in the 
total mTOR protein levels (phospho-mTOR/γtub normalized on control; mean ± s.e.m.: 
control 1.00 ± 0.03; rotenone 0.58 ± 0.09; oligomycin 0.81 ± 0.09; phospho-mTOR vs total 
mTOR median + IQr: control 1.00 (0.97, 1.03); rotenone 0.59 (0.56, 0.65); oligomycin 0.83 
(0.68, 0.89)). To further understand the possible involvement of mTORC1 in cell cycle 
changes, we measured PRAS40 as part of mTORC1 complex. We found that, after rotenone 
treatment, both phosphorylated and total PRAS40 protein levels were significantly reduced in 
IMCD3 cells (Fig.13E,F) (phospho-PRAS40/γtub normalized on control; mean ± s.e.m.: 
control 1.00 ± 0.03; rotenone 0.38 ± 0.11; oligomycin 0.73 ± 0.16; total PRAS40/γtub: 
control 1.00 ± 0.05; rotenone 0.59 ± 0.05; oligomycin 0.87 ± 0.08). mTORC1 is negatively 
regulated by AMPK, which responds to a decrease in cellular energy status. As consequence 
of ATP decrease after rotenone and oligomycin treatments, we found an increase in AMPK 
activation by phosphorylation (Fig.13H), but also a decreased in the total AMPK protein 
levels (Fig.13I) (phospho-AMPKα/total AMPKα normalized on control; median + IQr: 
control 1.0 (0.8, 1.2); rotenone 4.72 (2.6, 5.9); oligomycin 3.47 (2.8, 4.2)) (AMPKα/γtub 
normalized on control: mean ± s.e.m.: control 1.00 ± 0.07; rotenone 0.51 ± 0.12; oligomycin 
0.58 ± 0.05). Moreover, absolute AMPK phosphorylation tended to be increased 
(Sup.Fig.1G). To exclude that ciliary impairment was directly repressing mTOR pathway we 
generated stable Ift88 knock down IMCD3 cells. With our integrated shRNA we achieved a 
knock down similar to the one we observed after chemical treatments (mean ± s.e.m. 
IFT88/γtub protein LacZ 1.00 ± 0.02; Ift88KD 0.62 ± 0.02) (Sup.Fig.1H). However, we did 
not find any changes in mTOR phosphorylation state, indicating that the impairment of 
primary cilium was not the cause of decreased mTOR activation (Sup.Fig.1I).  
In conclusion, we found that mTORC1 repression decreased cell cycle progression and 
possibly protein synthesis in IMCD3. In fact, in IMCD3 the decreased total protein levels of 
PRAS40, AKT and AMPK indicate that protein synthesis was partly responsible for cilia 
impairment after rotenone and oligomycin treatments. 
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A decreased number of ciliated cells could also indicate the increase of apoptotic events that 
could trigger reabsorption of the cilium. Therefore, we investigated the amount of apoptotic 
and necrotic cells (Fig.13J). Rotenone treatment did not alter vitality and apoptosis compared 
to the control at the concentration we used (living cell %, mean ± s.e.m.: control 62.7 ± 0.7%; 
rotenone 65.0 ± 1.1%; dead apoptotic cells, median + IQr: control 10.8% (10.0,15.2); 
rotenone 8.8% (7.7,12.7)). Surprisingly, we found a significant protection against cell death 
using oligomycin (Fig.13J) (living cell %, mean ± s.e.m.: 76.8 ± 1.8%; dead apoptotic cells, 
median + IQr: 5.2% (4.3, 10.2)).  
In summary, we found fewer IMCD3 cells out of the cell cycle after rotenone treatment and, 
in a lower extent, using oligomycin. This result was in agreement with the mTOR activation 
status. The increase of cells in the S+G2M phases was not enough to justify the decrease in 
ciliated cells observed with rotenone or oligomycin treatments. Moreover, we demonstrated 
that early apoptotic events were not the trigger for cilium reabsorption. 
4.4.3 Rotenone Treatment Elongates Cilia in Human Retinal Epithelial Cells 
To what extent increase in ROS and/or energy depletion affect IMCD3 cell ciliation was not 
possible to discern, since both mitochondria inhibitors were responsible for ROS 
overproduction. Trying to uncover the cause of ciliary defect and to test if the effect of 
rotenone was cell-type specific, we used a different cell line used in ciliary studies namely 
human telomerase reverse transcriptase immortalized retinal pigmented epithelial 1 (h-TERT 
RPE1). Here, we found a dose-dependent increase in maximum and median ciliary length 
using rotenone (Fig.14A,B and Sup.Fig.2A, respectively) (maximum ciliary length 
normalized on control; median + IQr: control 1.00 (0.86, 1.12); rotenone 100nM 0.99 (0.82, 
1.25); 200nM 1.34 (1.04, 1.46); 400nM 1.68 (1.39, 1.96)); (median cilia length normalized 
on control; median + IQr: control 1.00 (0.92, 1.09); rotenone 100nM 0.96 (0.86, 1.02); 
200nM 0.96 (0.87, 1.1); 400nM 1.11 (1.02, 1.21)). It is worth to note that the minimum 
length was not altered (Fig.14B).  
To understand the link between the cilia elongation and a dose-dependent blockade of 
complex I and to find the correct dose of oligomycin that maximally inhibits the ATP linked 
respiration, we measured the OCR in response to acute treatments in RPE1 cells (Fig.14C and 
Sup.Fig.2B). We found that the OCR after acute rotenone treatment was decreased in a dose-
dependent manner up to 800nM, while oligomycin inhibition of ATPase was maximal 
already at 200nM (spare OCR%; mean ± s.e.m: rotenone 200nM 31.8 ± 0.7; 400nM 29.4 ± 
1.1; 800nM 25.5 ± 0.7; median + IQr oligomycin 200nM 37.8 (29.0, 42.6); 400nM 34.0 
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(27.8, 38.7); 800nM 33.8 (31.2, 35.7)). Thus, we chose concentration of 800nM rotenone and 
400nM oligomycin, treated the cells for 48h and measured again cilia length and number 
(Fig.14D-F and Sup.Fig.2C). Under these treatments the number of ciliated cells was 
unaltered (Fig.14D). Moreover, we again found an increase of median (Fig.14E) and 
maximum ciliary length (Fig.14F) using rotenone (median cilia length normalized on control; 
median + IQr: control 1.00 (0.97, 1.06); rotenone 1.20 (1.10, 1.36); oligomycin 0.96 (0.89, 
1.17)) (maximum cilia length normalized on control; median + IQr: control 1.00 (0.94, 
1.08); rotenone 1.94 (1.35, 2.11); oligomycin 0.95 (0.92, 1.07)).  
To understand whether the elongation of primary cilia due to rotenone treatment was 
accompanied by upregulation of anterograde transport along the axoneme, we measured the 
amount of IFT88 protein. Here, we did not find any significant changes in IFT88 protein 
levels (Sup.Fig.2D).  
Taken together, our results in RPE1 cells show that rotenone induced an elongation of cilia in 
a dose-dependent manner, without altering cilia number per cells. This effect was not 
accompanied by increase of proteins involved in ciliary transport.  
Figure 14. A) Representative images of RPE1 control (top panel) and treated with 400nM of rotenone (bottom panel) for 
48h. Cilia stained with anti-acetylated tubulin are indicated with white arrows. B) Quantification of dose-dependent effect 
of rotenone maximum (P<0.001) and minimum (P=0.12) cilia length in RPE1 cells. Data represent 3 experiments (n>12 
with minimum 20 cells each). Median + IQr, Kruskal-Wallis + Dunn´s. C) Oxygen consumption rate normalized to the 
baseline after addition of different doses of rotenone and oligomycin in RPE1. Data represent 3 experiments (n=18). Mean 
+ s.e.m ANOVA + Tukey P<0.001. D) Quantification of RPE1 ciliated cells treated 48h with 800nM rotenone (black) or 
400nM oligomycin (red). Data represent 3 experiments (n>15 with approximately 40 cells each). Median + IQr, Kruskal-
Wallis P=0.87. E) Quantification of the median ciliary length in RPE1 treated as above. Rotenone (black) Oligomycin 
(red). Data represent 3 experiments (n>15 with approximately 40 cells each). Median + IQr, Kruskal-Wallis + Dunn´s 
P<0.001. F) Quantification of the maximum ciliary length in RPE1 treated as above. Rotenone (black) Oligomycin (red).  
Data represent 3 experiments (n>15 with approximately 40 cells each). Median + IQr, Kruskal-Wallis + Dunn´s P<0.001.  
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4.4.4 Increased Mitochondrial ROS are Responsible for Ciliary Morphology 
Alteration in RPE1 cells 
To investigate whether or not cellular energy status was responsible for the morphological 
ciliary changes we observed in RPE1 cells, we measured adenosine nucleotides after 
treatments with rotenone and oligomycin. Here, we found that neither rotenone nor 
oligomycin reduced cellular ATP (Fig.15A) but oligomycin treatment increased the ADP 
levels (Fig.15A) resulting in a significantly decreased ATP/ADP ratio (Fig.15B) (ATP/ADP 
ratio normalized on control; mean ± s.e.m.: control 1.00 ± 0.02; rotenone 0.88 ± 0.04; 
oligomycin 0.66 ± 0.04) (nmoles ADP/mg protein normalized on the ATP levels; median + 
IQr: control 0.032 (0.030, 0.035); 0.037 (0.033, 0.044); 0.046 (0.040, 0.070)). We cannot 
exclude that using other methods to decrease ATP in RPE1 could result in reabsorption or 
failure of ciliary maintenance as seen in IMCD3. The reduced ATP/ADP ratio using 
oligomycin in RPE1, pointed out that ATP levels rather than ATP/ADP ratio affect ciliary 
maintenance in the two cell lines we studied.  
Further, we measured the activation of AMPK in response to the energy balance shift after 
the treatments (Fig.15C,E and Sup.Fig.2E). Both rotenone and oligomycin activated AMPK 
by means of phosphorylated levels (Fig.15E and Sup.Fig.2E) without affecting the total 
AMPKα (p-AMPKα/AMPKα normalized on the control; median + IQr: control 1.00 (0.96, 
1.37); rotenone 1.86 (1.13, 2.28); oligomycin 2.14 (1.49, 2.26)) (p-AMPKα/γtub normalized 
on the control; median + IQr: control 1.00 (0.96, 1.04); rotenone 1.98 (1.17, 2.31); 
oligomycin 2.09 (1.34, 2.55)). AMPK activation is a negative regulator of mTOR signaling 
(173, 176). In fact, we found that after 48h of treatments, the phosphorylated form of mTOR 
was decreased (Fig.15D,F and Sup.Fig.2F) (phospho-mTOR/mTOR normalized on control; 
median + IQr: control 1.00 (0.96, 1.04); rotenone 0.74 (0.62, 0.89); oligomycin 0.78 (0.64, 
0.89)) (phospho-mTOR/γtub normalized on control; mean ± s.e.m.: control 1.00 ± 0.09; 
rotenone 0.70 ± 0.7; oligomycin 0.73 ± 0.07). The total amount of mTOR protein was not 
affected (Sup.Fig.2F).  
Taking together, the results of the two cell lines showed that mTOR repression alone without 
a decrease of protein synthesis did not act as signaling for cilium reabsorption. In fact, in 
RPE1, AMPK phosphorylation in response to rotenone and oligomycin treatments led to a 
repression of mTOR, showing that in our experimental settings ciliary impairment could be 
consequence and not cause of reduced mTOR signaling. 
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Figure 15. A) ATP and ADP (nmol/mg protein) normalized on the control in RPE1 cells treated 48h with 800nM 
rotenone (black) or 400nM oligomycin (red). Data represent 3 experiments (n>5). Median + IQr, Kruskal-Wallis + 
Dunn´s ATP P=0.89; ADP P=0.02. B) ATP/ADP ratio in RPE1 treated 48h as above. Data represent 3 experiments 
(n>5). Mean + s.e.m ANOVA + Tukey P<0.001. C) Representative image of WB of phosphorylated and total AMPKα 
in RPE1 cells treated as above. D) Representative image of WB of phosphorylated and total mTOR in RPE1 cells treated 
as above. E) Quantification of C) p-AMPKα versus AMPKα. Data represent 4 experiments (n=7). Median + IQr, 
Kruskal-Wallis + Tukey P=0.001. F) Quantification of D) p-mTOR versus mTOR. Data represent 4 experiments (n=7). 
Median + IQr, Kruskal-Wallis + Tukey P=0.007. G) Cell cycle analysis with PI staining in RPE1 treated as above. 
Representative image of plot of cell cycle in control cells. Data represent 4 experiments (n>8 with 50000 events each). 
Median + IQr, Kruskal-Wallis + Tukey. G0-1 P=0.004; S P=0.50; G2M P=0.42. H) Quantification of Mitosox intensity in 
RPE1 cells treated as above. Data represent 5 experiments (n>10 of 50000 events). Median + IQr, Kruskal-Wallis + 
Dunn´s. P=0.001 I) Quantification of maximum ciliary length in RPE1 cells treated with 800nM of rotenone 48h in the 
presence of antioxidants (Tiron + Vit.C 1mM, retinoic acid 1uM). Data represent minimum 3 experiments (n>14). 
Median + IQr, Kruskal-Wallis + Dunn´s. P<0.001 J) Quantification of maximum ciliary length in RPE1 cells treated 
with 10nM rotenone in glucose-free galactose media. Data represent minimum 3 experiments (n=15). Median + IQr, 
Mann-Whitney. P<0.001. K) Quantification of median ciliary length in RPE1 cells treated as above. Data represent 
minimum 3 experiments (n=15). Mean + s.e.m., t-test. P<0.001.    
 63 
As mentioned before, cilia reabsorption and elongation is dependent of the cell cycle phase. 
Therefore, to explain the phenotype observed, we investigated the cell cycle as possible 
regulator of cilia length. After 5 days of starvation most of the RPE1 cells are in G0-1 phase 
(Fig.15G). We found a slight but significant decrease in G0-1 after rotenone treatment (median 
+ IQr arbitrary units: control 100.0 (99.6, 100.4); rotenone 97.0 (95.9, 98.5); oligomycin 
99.5 (98.9, 100.6)). We did not detect differences in the S and G2M phase.  
In contrast to IMCD3 cells, in RPE1 cells rotenone treatment was able to elongate the cilia. 
The effect was not dependent on the cellular energy status. Moreover, most of the RPE1 cells 
were found in G0-1 phase allowing us to exclude also the cell cycle as reason for the ciliary 
morphology change.  
We therefore shifted our attention to ROS as trigger for impaired cilia morphology. We found 
an increased mtROS generation after rotenone treatment (Fig.15H and Sup.Fig.2G) that was 
not reflecting an increase in cytosolic ROS (Sup.Fig.2H,I) (MitoSOX fluorescence intensity 
normalized on the control; median + IQr: control 1.00 (0.89, 1.11); rotenone 1.92 (1.42, 
1.98); oligomycin 1.18 (1.00, 1.36)). To be able to rescue the phenotype, we used the same 
antioxidant approach as for IMCD3 cells. In RPE1 cells we could not rescue the phenotype 
by means of maximum ciliary length (Fig.15I) and median ciliary length (Sup.Fig.2J). This 
can be due to the antioxidant mechanism of action and radical site in which the ROS are 
produced and eventually quenched. A previous study using RPE1 cells showed how the ROS 
production can be blocked or not depending on the compartment where they are generated 
(117, 177). 
To prove that the effect of rotenone on cilia morphology changes in RPE1 was due to 
mitochondrial ROS production and not unspecific effect of the drug, we decreased its 
concentration and used a glucose-free galactose culture media. Using galactose media the 
aerobic glycolysis is unfavorable and the cells use almost exclusively mitochondria as energy 
source. Here, using 10nM of rotenone for 48h we reproduced the increase in maximum 
ciliary length (Fig.15J) and median ciliary length (Fig.15K) that we found at higher rotenone 
concentrations using glucose media (maximum ciliary length normalized on control; median 
+ IQr: control 1.00 (0.91, 1.10); rotenone 1.44 (1.23, 1.71)) (median ciliary length 
normalized on control; mean ± s.e.m: control 1.00 ± 0.02; rotenone 1.22 ± 0.03). The similar 
phenotype observed using galactose culture in RPE1 treated with 80 fold less concentration 
of rotenone suggest that the elongation of cilia was due to redox signaling from mitochondria.  
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4.4.5 Mitochondria are in Close Relationship with Basal Body 
More than 1000 proteins are identified and classified in the ciliary proteome. Searching a 
database of predicted or bona fide ciliary proteins (CiliaDB (178)) that combines results from 
high throughput proteomics, differential expression and comparative genomics studies, we 
found listed several mitochondrial proteins (Table 6). These proteins included, but were not 
limited to, subunits of mitochondrial complexes as well as transporters involved in ATP 
generation and ETC from a variety of organisms including humans. 
Name Ciliary 
evidence 
Organisms with 
ciliary evidence 
Non Flagellary 
evidence 
Proteomic 
studies 
Evidence in 
Hsapiens 
Ubiquinol-cytochrome c reductase 
core protein II  
6 4 3 3 0 
NADH dehydrogenase (ubiquinone) 
Fe-S protein 1, 75kDa (NADH-
coenzyme Q reductase) 
5 5 2 1 1 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide  
5 5 1 1 1 
Creatine kinase, mitochondrial 1B  5 3 2 2 1 
Isocitrate dehydrogenase 2 (NADP+), 
mitochondrial  
5 5 3 3 1 
Inner membrane protein, 
mitochondrial 
5 4 3 3 1 
Acyl-CoA dehydrogenase, 
short/branched chain  
5 2 3 0 1 
Voltage-dependent anion channel 2 5 4 4 3 0 
Solute carrier family 25 
(mitochondrial carrier; phosphate 
carrier), member 3  
4 4 4 2 1 
Solute carrier family 25 
(mitochondrial carrier; dicarboxylate 
transporter), member 10 
4 3 3 3 0 
Table 6. List of the 10 most represented mitochondrial proteins found in the ciliary database ordered by ciliary evidence.  
To investigate the spatial relationship and the possible properties of mitochondrial subsets in 
the proximity of the cilium, we generated stable IMCD3 cell lines overexpressing a cilia-
specific protein, ADP-ribosylation factor-like protein 13b tagged with Venus (ARL13b-
Venus) or RFP together with a photoactivatable GFP targeted to the mitochondrial matrix 
(subunit VIII of cytochrome c oxidase) (Mito-PAGFP) (Fig.16A-D). In IMCD3 ARL13b-
Venus cells stained with Mitotracker Deep Red (Fig.16A) and IMCD3 ARL13b-RFP-Mito-
PAGFP (Fig.16B,C), we observed a subset of mitochondria in proximity to the cilium both 
during growth (Fig.16B) and at confluence after starvation (Fig.16A,C).  
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To test if the subsets of mitochondria close to the basal body displayed different bioenergetics 
properties, we measured their Δψm and compared it to the cellular average of all mitochondria 
using the potentiometric dyes TMRE (Fig.16D,E) and JC-1 (Sup.Fig.2L,M). 
We selected as ciliary mitochondrial subset the mitochondria within 2µm distance around the 
cilium (Sup.Fig.2K). Comparing Δψm of these subsets in proximity of the cilium with the 
average Δψm of the whole mitochondrial network, we did not detect any significant difference 
in IMCD3 at confluence in basal medium culture condition with both fluorescent dyes 
(Fig.16E and Sup.Fig.2M). These results suggest that mitochondria in proximity of the 
primary cilia have a similar metabolism and are in equilibrium with the intracellular 
mitochondrial network, under the chosen conditions.  
Figure 16. A) Representative image of live recording of stable cell line IMCD3 Arl13b-GFP loaded with 25nM 
Mitotracker Deep Red FM. In the zoomed box the plane was rotated using Imaris software to show the mitochondrial 
subset close to the cilium. B) Representative image of stable IMCD3 cell line Arl13b-RFP-Mito-PAGFP during growth. 
C) Imaris 3D rendering of a singular cilium in IMCD3 Arl13b-RFP-Mito-PAGFP and mitochondrial network at 
confluence. D) Representative cropped image of IMCD3 Arl13b-venus stained 1h with 25nM TMRE. E) Mitochondrial 
membrane potential of mitochondria within <2µm from the cilium compared to the overall cell mitochondrial network 
measured with TMRE in IMCD3 Arl13b-Venus stable cell line. Data represent 3 experiments (n=15 with approximately 
20 cells each). Mitochondria close to the cilium Mean + CI 0.85-1.17. 
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4.4.6 Ciliation is Impaired in Kidney of a Diabetic Nephropathy Mouse Model  
To the best of our knowledge, the results showed above are the first demonstrating an effect 
of internal radical production on cell ciliation. Previously, high doses of the radical inducer 
hydrogen peroxide have been proven to decrease ciliation in MDCK cells. The same effect 
was achieved after ischemic injury in kidney (179). 
It has been previously described that during diabetic nephropathy, kidneys are subjected to 
increased oxidative stress, mitochondrial dysfunction and probably hypoxia (67, 84, 102, 105, 
180). We used the db/db mouse model to translate our finding of decreased ciliation in 
IMCD3 cells, to diabetic nephropathy in vivo (Fig.17). The db/db mice have been widely 
used as a model of human diabetic nephropathy because of their common features (181). 
Whereas at 8 weeks of age kidneys from db/db mice were functionally and morphologically 
normal, at week 24 the blood creatinine levels were significantly higher and kidney 
morphology was altered, indicating the progression of nephropathy (Fig.17A-C) (non-fasting 
plasma creatinine (µmol/L) mean ± s.e.m. 8 weeks: wt 71.9 ± 9.9; db/db 68.5 ± 8.6; 24 weeks 
wt 123.1 ± 12.6; db/db 284.6 ± 30.0). At 8 weeks of age db/db mice were already 
hyperglycemic, obese and hyperinsulinemic compared to control littermates (Fig.17D and 
Sup.Fig.3A,C) (non-fasting blood glucose (mmol/L) mean ± s.e.m. 8 weeks: wt 5.67 ± 0.02; 
db/db 20.58 ± 2.49; 24 weeks: wt 5.27 ± 0.31; db/db 21.00 ± 3.00). Moreover, 
hyperleptinemia was observed in both 8 weeks and 24 weeks old db/db mice to a similar 
extent (Fig.17E) (non-fasting plasma leptin (ng/ml) mean ± s.e.m. 8 weeks: wt 0.89 ± 0.09; 
db/db 41.98 ± 5.74; 24 weeks: wt 2.45 ± 0.38; db/db 46.74 ± 3.20). Using kidney sections we 
investigated the number and morphology of cilia in two different medullary cell types such as 
collecting duct and distal tubules cells. In the medullary collecting duct cells (Fig.17F), which 
correspond to IMCD3 cells in vitro, we found a robust and consistent significant decrease in 
cilia number (Fig.17G) and cilia length (Fig.17H) in db/db mice at 24 weeks of age (ciliated 
collecting duct cells (%); median + range 8 weeks: wt 57.6 (54.5, 60.2); db/db 57.4 (53.2, 
58.8); 24 weeks: wt 52.6 (49.0, 57.0); db/db 27.0 (13.4, 30.5) (ciliary median length (µm); 
median + range 8 weeks: wt 3.04 (2.79, 3.14); db/db 3.34 (3.02, 3.54); 24 weeks: wt 3.30 
(3.26, 3.32); db/db 2.41 (2.22, 2.79)).  
To understand whether the phenotype was extended to other parts of the kidney we analyzed 
in the identical manner cilia of distal tubules cells (Fig.17I-K). Here we found a decrease in 
number of ciliated cells (Fig.17J) in 24 weeks old db/db mice without alteration of length in 
the remaining cilia (Fig.17K) (ciliated distal tubules cells (%); median + range 8 weeks: wt 
60.5 (56.7, 63.4); db/db 48.6 (35.7, 62.5); 24 weeks: wt 46.8 (30.4, 58.4); db/db 14.6 (11.9, 
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27.9) (ciliary median length (µm); median + range 8 weeks: wt 2.48 (2.29, 2.69); db/db 2.40 
(2.12, 2.42); 24 weeks: wt 2.67 (2.42, 2.82); db/db 2.59 (2.03, 2.80)). 
Figure 17. A) Non-fasting plasma creatinine in wt and db/db mice at 8 (n=4) and 24 (n=3) weeks of age. Mean ± s.e.m 
ANOVA+Tukey P<0.0001. B) Representative morphological kidney sections (20µm) counterstained with hematoxylin-eosin 
of 8 weeks wt (B´ and B´´) and db/db mouse (B´´and B´´´´). B´´´and B´´´´represent the magnification of the squares in B´ and 
B´´. C) Representative morphological kidney sections (20µm) counterstained with hematoxylin-eosin of 24 weeks wt (C´ and 
C``) and db/db mouse (C´´and C´´´´). C´´´and C´´´´represent the magnification of the squares in C´ and C´´. D) Non-fasting 
blood glucose in wt and db/db mice at 8 and 24 weeks of age (n=4 each group). Mean ± s.e.m ANOVA+Tukey P<0.0001. E) 
Non-fasting plasma leptin in wt and db/db mice at 8 (n=4) and 24 (n=3) weeks of age. Mean ± s.e.m ANOVA+Tukey 
 68 
P<0.0001. F) Representative images of kidney sections (one stack) double stained with acetylated tubulin (green) for cilia 
measurement and aquaporin-2 (red) to identify collecting duct cells. Nuclei (blue) were counterstained with DAPI. F´ wt 8 
weeks; F´´db/db 8 weeks; F´´´wt 24 weeks; F´´´´ db/db 24 weeks. G) Percentage of ciliated collecting duct cells in wt and 
db/db mice at 8 and 24 weeks of age. Data represents 3 medullary images (upper, middle and lower kidney) in duplicates for 
each mouse (n=4). Minimum 10 collecting duct cells have been counted for each image. Median + IQr and range (n=4).  
ANOVA + Bonferroni P<0.0001. H) Cilia length of collecting ducts cells in wt and db/db mice at 8 and 24 weeks of age. 
Data is represented as mentioned above. Median + IQr and range (n=4).  ANOVA + Bonferroni P<0.0001. I) Representative 
images of kidney sections (one stack) double stained with acetylated tubulin (green) for cilia measurement and Na+-K+ 
ATPase (red) to identify distal tubules cells. Nuclei (blue) were counterstained with DAPI. I´ wt 8 weeks; I´´db/db 8 weeks; 
I´´´wt 24 weeks; I´´´´ db/db 24 weeks. J) Percentage of ciliated distal tubules cells in wt and db/db mice at 8 and 24 weeks of 
age. Data is represented as mentioned above. Median + IQr and range (n=4).  ANOVA + Bonferroni P=0.0003. K) Cilia 
length of distal tubules cells in wt and db/db mice at 8 and 24 weeks of age. Data is represented as mentioned above. Median 
+ IQr and range (n=4).  ANOVA + Bonferroni P=0.33.  
These results show that ciliogenesis or cilia maintenance are altered during diabetic 
nephropathy in at least two different cell types. Although a defective ciliogenesis have been 
found in neurons during hyperleptinemia (182, 183), in 8 weeks old db/db mice ciliogenesis 
was not impaired in the presence of leptin levels similar to 24 weeks old db/db mice. For the 
same reason, we also excluded altered lipid profile as possible causes of ciliary 
derangements. However, we cannot fully exclude a role for adiponectin and insulin in the 
phenotype we observed due to their decrease in 24 week old db/db mice (Sup.Fig.3B,C). 
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Supplementary Figure 1. A) Representation of flow cytometric histogram of IMCD3 stained with MitoSOX. Green: 
unstained, red: control, blue: rotenone, orange: oligomycin. B) Representation of flow cytometric histogram of IMCD3 
stained with DCFDA. Green: unstained, red: control, blue: rotenone, orange: oligomycin. C) Quantification of dose 
dependent effect of TBOOH on number of ciliated IMCD3 cells. Data represent 3 experiments (n=14 with approximately 20 
cells each). Mean ± s.e.m ANOVA P=0.69. D) Quantification of DCFDA intensity in IMCD3 cells after 48h treatment with 
different doses of TBOOH. Data represent 3 experiments (n=6). Mean ± s.e.m ANOVA P=0.28. E) Quantification of the 
effect of paraquat on number of ciliated IMCD3 cells. Data represent 3 experiments (n=14 with approximately 20 cells each). 
Mean ± s.e.m t-test P=0.99. F) Quantification of Fig.13E p-PRAS40 versus PRAS40 in IMCD3 treated for 48h with 25nM 
rotenone, 50nM oligomycin. Data represent 3 experiments (n>6). Mean + s.e.m ANOVA P=0.14. G) Quantification of 
Fig.13G p-AMPKα versus loading control in IMCD3 treated as above. Data represent 3 experiments (n>6). Median + IQr, 
Kruskal-Wallis P=0.08. H) Representative WB image of IFT88 protein from LacZ and Ift88KD stable IMCD3 and 
 70 
quantification of IFT88 protein levels. Data represent 4 experiments (n=6). Mean ± s.e.m t-test P<0.001. I) Representative 
WB image of mTOR protein from LacZ and Ift88KD stable IMCD3 and quantification of pmTOR/mTOR ratio. Data 
represent 4 experiments (n=6). Mean ± s.e.m t-test P=0.12. The number 1 and 2 represent two different transductions used to 
generate Ift88 stable cell lines. 
Supplementary Figure 2. A) Quantification of dose-dependent effect of rotenone on median cilia length in RPE1 cells 
treated 48h. Data represent 3 experiments (n>12 with >20 cells each). Median +IQr, Kruskal-Wallis + Tukey P=0.031. B) 
Representative experiment of cellular respiration (OCR) normalized to the baseline after addition of different doses of 
rotenone and oligomycin in RPE1. Mean ± s.e.m. C) Representative images of RPE1 cell line treated 48h with 800nM 
rotenone (rot) or 400nM oligomycin (oli). Examples of cilia are indicated with white arrows. The top left box represents the 
staining in single channels. D) Representative image of WB of IFT88 protein in RPE1 treated as above and quantification of 
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IFT88 protein levels. Data represent 3 experiments (n>6). Mean ± s.e.m. P=0.50. E) Quantification of Fig.15C in RPE1 cells. 
Median + IQr phospho-AMPKα/total AMPKα control 1.00 (0.96, 1.04); rotenone 1.86 (1.13, 2.28); oligomycin 2.14 (1.49, 
2.26) Kruskal-Wallis + Tukey P=0.003; AMPKα/γtub Kruskal-Wallis P=0.3. Data represent 4 experiments (n=7). F) 
Quantification of Fig.15D in RPE1 cells. Mean ± s.e.m. phospho-mTOR/γtub control 1.00±0.09; rotenone 0.70±0.07; 
oligomycin 0.73±0.07. ANOVA + Tukey P=0.031; mTOR/γtub Kruskal-Wallis P=0.88. Data represent 4 experiments (n=7). 
G) Representation of flow cytometric histogram of RPE1 stained with MitoSOX. Green: unstained, red: control, blue: 
rotenone, orange: oligomycin. H) Quantification of DCFDA intensity in RPE1 cells treated as above. Data represent 3 
experiments (n=6 of 50000 events). Mean ± s.e.m., ANOVA. P=0.27 I) Representation of flow cytometric histogram of RPE1 
stained with DCFDA. Green: unstained, red: control, blue: rotenone, orange: oligomycin. J) Quantification of median ciliary 
length in RPE1 cells treated with 800nM of rotenone 48h in the presence of antioxidants (Tiron + Vit.C 1mM, retinoic acid 
1uM). Data represent minimum 3 experiments (n>14). Median + IQr, Kruskal-Wallis + Dunn´s. P<0.001. K) Example of 
rendering with Imaris software used for JC1 and TMRE intensity quantification. Rendering colors: mitochondria (green), 
cilium (red), subset of selected mitochondria (yellow) within 2µM distance from the primary cilium. L) Representative 
cropped image of stable ARL13b-RFP-mito-PAGFP IMCD3 stained with JC1. M) Quantification of JC-1 red/green ratio 
normalized on the entire cell mitochondria (black) of the mitochondrial subset in proximity of the cilium (white). Data 
represent 2 experiments (n=8 approximately 20 cells each). Mitochondrial ciliary selected subset Mean + CI 0.98-1.12. 
Supplementary Figure 3. A) Body weight of wt and db/db mice at 8 and 24 weeks of age (n=4 each group) P<0.0001. B) 
Plasma adiponectin in wt and db/db mice at 8 (n=4) and 24 weeks (n=3) of age. P=0.0011. C) Plasma C-Peptide in wt and 
db/db mice at 8 (n=4) and 24 weeks (n=3) of age. P=0.044. D) Blood cholesterol in wt and db/db mice at 8 (n=4) and 24 
weeks (n=3) of age. P=0.0067. E) Blood triglycerides in wt and db/db mice at 8 (n=4) and 24 weeks (n=3) of age. P=0.086. F) 
Liver triglycerides in wt and db/db mice at 8 (n=4) and 24 weeks (n=3) of age. Data are presented as mean ± s.e.m ANOVA + 
Tukey P<0.0001.   
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4.5 PRELIMINARY RESULTS II: RELATIONSHIP BETWEEN MTDNA COPY 
NUMBER AND CELLULAR ENERGY METABOLISM IN MIN6M9 AND 
IMCD3 CELL LINES 
Mitochondrial DNA (mtDNA) copy number as well as mitochondrial mass are tissues 
specific and likely reflect different energy requirements (184). MtDNA depletion is a 
particular condition observed in cardiovascular disease, diabetes and cancer and might impair 
mitochondria and metabolic function of target tissues (49, 184). Moreover, a reduction in 
ATP production can be due to decrease in mtDNA in several tissues during aging (185). 
As mentioned in the introduction (see 1.2.4), mtDNA and its transcription factor TFAM are 
in equilibrium with each other. Although much progress has been made in the understanding 
of the mtDNA replication, its mechanisms are still not clear. In this project we aimed to 
understand the relationship between the amount of mtDNA and mitochondrial bioenergetics.  
4.5.1 Transient or Stable TFAM Knock Down Effects on Mitochondrial 
Respiration and ATP Levels in min6m9 and IMCD3 Cells 
To investigate the relationship between mtDNA copy number and mitochondrial function, we 
generated shRNA (186) targeting Tfam. Using a commercially available adenoviral vector, 
we reduced Tfam mRNA in min6m9 and IMCD3 cells by 66.0 ± 3.2% and 71.5 ± 6.5% 
respectively (mean ± s.e.m.; 
Fig.18A). The reduction in 
gene expression was 
proportional to TFAM 
protein levels and mtDNA 
in min6m9 measured after 
one week of transduction 
(mean ± s.e.m. 53.9 ± 4.4% 
and 52.6 ± 4.3%, 
respectively) (Fig.18B,C).  
Despite the decrease of 
mtDNA in min6m9, which 
use almost exclusively 
mitochondria as energy 
source, we did not detect 
changes in the OCR upon glucose stimulation (Fig.18D) and ATP/ADP ratio (mean ± s.e.m.: 
LacZ 25.2 ± 0.5, Tfam KD 24.5 ± 1.3) (Fig.18E).  
Figure 18. Adenoviral Transduction A) Tfam mRNA levels in min6m9 and 
IMCD3. Mean ± s.e.m  2 experiments n=4. B) TFAM protein expression in 
min6m9. Mean ± s.e.m  3 experiments n=6. D) mtDNA/nDNA ratio in min6m9. 
Mean ± s.e.m  2 experiments n=4 E) OCR normalized on baseline in glucose-
stimulated min6m9. Mean + CI 1 experiment n=30. F) ATP/ADP ratio min6m9. 
Mean ± s.e.m  2 experiments n=3 White bar Lacz; black bar Tfam. 
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To overcome the limit of shRNA transient expression associated with adenoviral delivery, we 
generated cell lines stably expressing the shRNA targeting Tfam. This strategy has been 
successfully used to decrease mitochondrial energy production in human bone osteosarcoma 
cells and mouse embryonic cells (187, 188). Thus, we used lentivirus to integrate the shRNA 
into the cells genome. One month after transduction and blasticidin selection, IMCD3 cells 
showed decreased Tfam mRNA and protein as well as mtDNA levels (mean ± s.e.m. decrease 
in Tfam: mRNA 49.8 ± 5.6%, protein 59.5 ± 3.9% and mtDNA COX vs S18 60.0 ± 2.7% and 
S12 vs S18 62.8 ± 7.2%) (Fig.19A-C). Even more pronounced decline in protein expression 
was found in min6m9 stable cell line (mean ± s.e.m. decrease in TFAM 78.2 ± 3.6%) 
(Fig.19D).  
 
 
 
 
 
 
Figure 19. Stable cell lines. White = Control LacZ; Black Tfam KD. A) Tfam mRNA levels in IMCD3 stable KD. Mean ± 
s.e.m  3 experiments n=8. B) TFAM protein expression in IMCD3. Mean ± s.e.m  4 experiments n=6. C) mtDNA/nDNA in 
IMCD3. Left COX vs S18 and right S12 vs S18. Mean ± s.e.m 2 experiments n=3. D) TFAM protein expression levels in 
min6m9. Mean ± s.e.m 2 experiments n=7. 
Surprisingly, the mitochondrial OCR was not altered in both min6m9 and IMCD3 stable cell 
lines compared to the control (Fig.20A,B) (OCR normalized on LacZ. Mean + CI; IMCD3 
cells: Basal LacZ 1.00 (0.98, 1.01); Tfam KD 0.96 (0.92, 0.99); Oligomycin LacZ 0.13 (0.12, 
0.14), Tfam KD 0.16 (0.15, 0.17); FCCP LacZ 3.28 (3.13, 3,44) Tfam KD 3.45 (3.20, 3.70). 
Min6m9 cells: Basal LacZ 1.00 (0.96, 1.04); Tfam KD 1.12 (1.05, 1.19); Oligomycin LacZ 
0.27 (0.24, 0.30), Tfam KD 0.28 (0.26, 0.30); FCCP LacZ 1.11 (1.03, 1.18) Tfam KD 1.48 
(1.31, 1.69)). To force IMCD3 cells to rely mainly on mitochondrial OXPHOS for ATP 
production we used a glucose-free media supplemented with galactose. It is worth to note that 
in this medium the cell growth was significantly reduced indicating a decrease in cellular 
energy. As expected, galactose culture decreased basal and maximum respiration (Fig.20B) 
(OCR normalized on LacZ cultured in glucose media. Mean + CI; Basal LacZ 0.72 (0.67, 
0.78); Tfam KD 0.84 (0.75, 0.92); Oligomycin LacZ 0.11 (0.09, 0.13), Tfam KD 0.11 (0.09, 
0.13); FCCP LacZ 1.57 (1.47, 1.68) Tfam KD 1.70 (1.56, 1.85)). However, the difference 
between cells expressing shRNA against Tfam and control (LacZ) was negligible. In line with 
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the respiration data, the ATP/ADP ratio was not changed compared to the control in IMCD3 
(Fig.20D). Preliminary data from min6m9 showed a slight but significant decrease in 
ATP/ADP ratio suggesting that these cells might be affected by long-term depletion of 
mtDNA (Fig.20C) (ATP/ADP ratio mean ± s.e.m.: LacZ 1.00 ± 0.05 and Tfam KD 0.76 ± 
0.07).  
 
 
Figure 20. A) OCR in min6m9 stable cells normalized on basal respiration (left columns) after addition of 1µM oligomycin 
(central columns) and 7µM FCCP (right columns). Mean + CI 3 experiments. B) OCR in IMCD3 stable cells normalized on 
basal respiration and addition as above. Mean + CI 3 experiments. C) ATP/ADP ratio min6m9 stable cell. Mean ± s.e.m 2 
experiments n=8. D) ATP/ADP ratio IMCD3 stable cell. Mean ± s.e.m 2 experiments n=8. 
Co
ntr
ol
Tfa
m 
KD
Co
ntr
ol
Tfa
m 
KD
Co
ntr
ol
Tfa
m 
KD
0.0
0.5
1.0
1.5
2.0
Min6m9 stable (Mean+CI 3 exp)
O
C
R
 (f
ol
d 
ch
an
ge
)
Baseline Oligomycin FCCP
Co
ntr
ol 
Gl
u
Co
ntr
ol 
 G
al
Tfa
m 
KD
 G
lu
Tfa
m 
KD
 G
al
Co
ntr
ol 
 G
lu
Co
ntr
ol 
 G
al
Tfa
m 
KD
 G
lu
Tfa
m 
KD
 G
al
Co
ntr
ol 
 G
lu
Co
ntr
ol 
 G
al
Tfa
m 
KD
Gl
u
Tfa
m 
KD
 G
al
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
 IMCD3 Oxygen Consumption Rate (Mean+CI 3 exp)
O
C
R
 (f
ol
d 
in
cr
ea
se
)
Baseline Oligomycin FCCP
Co
nt
ro
l g
lu
Co
nt
ro
l g
al
 Tf
am
 K
D 
glu
Tf
am
 K
D 
ga
l
0.0
0.5
1.0
1.5
A
T
P
/A
D
P
 r
at
io
 (f
o
ld
 in
cr
ea
se
)
IMCD3 ATP/ADP (Mean+SD 2 exp n=8)
Co
nt
ro
l g
lu
 Tf
am
 K
D 
glu
0.0
0.5
1.0
1.5
A
T
P
/A
D
P
 r
at
io
 (
fo
ld
 in
cr
ea
se
)
Min6m9 ATP/ADP (Mean+CI 2 exp n=8)
White = LacZ glucose 
Light grey = LacZ galactose  
Black = Tfam KD glucose 
Dark grey = Tfam KD galactose. 
A B 
C
 
D 
 75 
5 SUMMARY 
1. Acute and long-term hyperglycemia caused a metabolic switch from oxidative 
phosphorylation to aerobic glycolysis in human healthy primary fibroblasts and 
endothelial cells. Transient acute alteration of mitochodrial respiration and 
intermembrane potential, as well as long-term reduction in cell proliferation, was due to 
hyperosmotic effect of high glucose. Prolonged exposure to high glucose decreased 
mitochondria steady-state and uncoupled respiration together with reduced ATP/ADP 
ratio without changes in mitochondria number, ROS production and cellular 
NAD+/NADH ratio. Thus, in diabetes conditions, hyperglycemia in combination with 
hypoxia, inflammation and/or paracrine factors may be the cause of mitochondria 
dysfunction, ROS production and later complications.  
2. In pancreatic islets, both high oxygen tension and hypoxia reduced mitochondria content 
and function, induced apoptosis and impaired glucose-stimulated insulin secretion. 
Preconditioning of pancretic islets using the K+ATP channel opener diazoxide protected 
against hypoxia. Thus, diazoxide preconditioning could improve transplanted pancreatic 
islets yield and function protecting them from the hypoxic environment during 
engrafment and revasculatization. 
3. Primary cilia/basal body defect was associated with an impaired glucose-stimulated 
insulin release linked to the absent translocation of insulin receptor A to the cilium. 
Ciliary impairement had no effect on mitochondrial or cellular energy metabolism in 
vitro. A defective ciliogenesis was also found in β-cells of a diabetic rat model. Our in 
vitro studies indicated that decrease in ATP and increase in mitochondria ROS 
production impair cilia morphology and number. Altered cilia morphology and number 
was also found in vivo in diabetic nephropathy where the kidneys are characterized by 
increased ROS production and altered mitochondria metabolism. Conditions of 
decreased cellular energy levels and/or increased ROS production can potentially affect 
ciliary function. Dysfunctional cilia impairs insulin signaling and may also be associated 
with progression of diabetes complications. 
 
4. mtDNA depletion by 60-80%, which in some extent has been found during diabetes, did 
not alter mitochondrial metabolism in two different cell types. 
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
6.1 PAPER I 
The pathogenic mechanisms leading to the complications of diabetes are yet to be clarified in 
order to develop strategies to counteract the progression of the disease. The primary cause 
triggering these deleterious pathways is hyperglycemia, which characterizes the diabetic 
disease. However, how high glucose levels are involved in the development of diabetes 
complications is still a matter of extensive research and debate. Several theories have been 
suggested in the last decades, the latest of which put mitochondria as source of metabolic and 
redox imbalance observed in vivo. Mitochondrial defects, overproduction of ROS and cellular 
redox imbalance are features of tissues exposed to the diabetic milieu but can either be cause 
or consequence of the disease.  
Trying to unravel the pathogenic mechanism accounting for the metabolic defects during 
hyperglycemia, several works have been conducted using cell lines. In our work, we showed 
that healthy primary human cells exposed to hyperglycemia decrease their OXPHOS and 
shift their metabolism towards aerobic glycolysis. The increase in lactate levels due to 
hyperglycemia we found is in good agreement with previous works in cell lines and tissues 
(189, 190). Long-term hyperglycemia decreases cellular energy levels, maximal respiration 
without alteration in mitochondrial number or ROS production. These adjustments to the 
hyperglycemic milieu in healthy cells point out that other additive factors, such as time of 
exposure, hypoxia and paracrine mediators, might be necessary to exacerbate the deleterious 
effect of glucose. Moreover, the effect of these factors might be related to the characteristics 
of the cells composing that specific tissue. 
In this work, we showed that hyperosmosis could alter acutely the cell metabolism, 
bioenergetics and growth. The intermittent negative effect of high osmotic pressure on 
mitochondrial and cellular function might be partly responsible for diabetes complications. In 
our opinion, our results help to better understand the mitochondrial and metabolic changes 
induced by high glucose. Monitoring cellular metabolic changes in vivo with novel 
technologies is necessary to reveal the primary mechanisms leading to the complications of 
diabetes in kidney, neurons, heart and vasculature, as well as during wound healing. 
6.2 PAPER II AND III 
In these two works we studied possible approaches to improve islets functionality and yield 
after transplantation using the K+ATP channel opener diazoxide or high oxygen tension 
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pretreatments. We sought first to confirm the deleterious metabolic effect of hypoxia in islets 
in vitro. Here, we found a decrease in mtDNA, mitochondrial complexes, glucose oxidation 
and ATP production following hypoxia and re-oxygenation.  
Although hyperbaric chamber treatment and consequent hyperoxia is a valid coadjuvant 
treatment during transplantation, in our work pretreatment of isolated islets did not protect 
from the following hypoxia. The metabolic and mitochondrial impairments we found during 
hyperoxia are in agreement with other studies, in which decreased basal and spare respiratory 
capacity, and OXPHOS impairment in vitro were described (191, 192). Lastly, interpretation 
of hyperoxia and hypoxia regarding cellular respiration needs to be contextualized in vivo. In 
fact, in vitro measurements do not reflect the in vivo levels of oxygen in tissues and blood, 
especially regarding high oxygen tension (193).   
Preconditioning of tissues or cells using different drugs has been proven to be effective 
against short periods of ischemia and thus hypoxia. In the current view, preconditioning 
activates cellular defenses against injuries, which depends on the energy metabolism and 
electrical activity of the cells. Although works on preconditioning effects have been carried 
out mostly in the heart, similar results have been obtained in brain, skeletal muscle, kidney 
and liver (161). One of the molecules mimicking preconditioning is the K+ATP channel opener 
diazoxide. This compound has been shown to activate K+ATP channels present both in the 
cellular surface and mitochondria, depending on cell type. Moreover, it can inhibit succinate 
dehydrogenase, ATP synthase and act as mitochondrial uncoupler (161). In line with works 
where diazoxide have been used during ischemia or ischemia/reperfusion, we found a 
protective effect of diazoxide preconditioning against hypoxia in pancreatic islets. This was 
due to a decrease in necrosis that we explained by a prolonged similar-resting state of the 
islets. The protective effect might be also via the induced increase in HIF1α and AMPK, 
which enable adaptation to hypoxia (30). Finally, in our work we found a positive effect of 
preconditioning with diazoxide, which has not been previously investigated, opening a new 
potential pretreatment to improve yield and function of transplanted islets. 
6.3 PAPER IV 
Ciliopathies are a heterogeneous class of genetic disorders that display different or similar 
phenotypes depending of the genes involved (see 1.3.2). Beside the most common 
manifestations of ciliopathies, Bardet-Biedl and Alström syndromes present obesity and high 
comorbidity with diabetes.  
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In our work we found that cilia/basal body impairment led to β-cells dysfunction, especially 
regarding first phase insulin secretion. We suggest that these impairments are due to the 
localization of IR-A isoform to the cilium in β-cells during insulin stimulation. When insulin 
signaling was disrupted due to ciliary defects, reduction of SNARE complex by decreased 
PI3K/FOXO1 transcriptional regulation affected the first-phase of insulin secretion. 
Corroborating this hypothesis, Bbs4-/- mice displayed impaired glucose tolerance at the 
moment in which they had the same weight compared to wild type littermates. Our findings 
are strictly related to the localization of the IR-A to the cilium after stimulation in insulin 
secreting cell, proved by the fact that depletion of a trafficking protein necessary for ciliary 
function (OFD1) produced results similar to BBS protein deficiency.  
In the current work, we provide in vivo evidence of defective ciliogenesis in pancreatic islet 
of a rat model of diabetes (GK rats). The fact that other ciliopathies than Bardet-Biedl and 
Alström syndromes do not exhibit diabetes and/or obesity could be due to the gene and tissue 
involved in ciliary defects. However, it is also possible that diabetes or hyperglycemia is the 
cause of ciliary defect we found in β-cells. In this case, the ciliary impairment can establish a 
vicious cycle due to the recruitment of IR-A to the cilium during insulin stimulation. Further 
studies are needed to understand the IR-A specific signaling pathway through the cilium, in 
order to find novel strategy to increase insulin secretion from β-cells.  
In conclusion, we found that cilia/basal body impairment led to β-cells dysfunction, and 
defective ciliogenesis in a rat model of diabetes. We suggest that these impairments are due 
to the localization of IR-A isoform at the cilium in β-cells upon insulin stimulation. However, 
the effect of diabetes per se and the activation of deleterious pathway that accompany the 
disease (e.g. ROS production or energy metabolism) in relation to the primary cilium should 
be studied not only in pancreas but also in other tissues to understand the cause/consequence 
relationship between diabetes and ciliary signaling. 
6.4 PRELIMINARY RESULTS I 
In the last decades the primary cilium has emerged as signaling organelle (113-117, 194). For 
its maintenance, it might be speculated that ciliary machinery requires a great amount of 
energy. However, to what extent energy depletion can affect ciliary assembly and 
morphology, thus potentially altering its functions, is not known.  
Using two different cell lines (IMCD3 and RPE1), we found that interference with 
mitochondrial metabolism resulting in ATP depletion and ROS overproduction impairs 
primary cilium maintenance and morphology. Moreover, we found a subset of mitochondria 
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closer to the cilium, which displays a mitochondrial intermembrane potential similar 
compared to the one of the rest of the cell, indicating that this subset is in equilibrium with 
the intracellular mitochondrial network. 
In line with in vitro findings, we showed ciliary impairment in at least two different kidney 
cell types in a diabetic mouse model (db/db mouse) during nephropathy. In db/db mice 
during diabetic nephropathy sustained ROS production and metabolic derangements have 
been previously described, thus supporting our hypothesis that cilia can be affected by these 
causes (67, 84, 102, 105, 180).  
In conclusion, we described for the first time that interfering with the energy status of the 
cells impaired cilia formation or maintenance. We showed that ATP levels but not changes in 
ATP/ADP ratio could be critical to maintain primary cilia at least via protein synthesis. 
Moreover, we suggest that in both IMCD3 and RPE1 cell types, the impairment in ciliation 
could be due to a small amount of radicals for prolonged period of time acting as signaling 
molecules. The in vivo evidence of ciliary impairments in a mouse model that closely 
represents the human progression of diabetic nephropathy is also a novel finding. However, 
further studies would be needed to clarify the mechanisms by which ROS affects cilia and 
their functions in different cell types.  
Since mitochondrial radical production and energy balance are impaired during aging and 
other disease states, it would be important to further study ciliary function and morphology in 
different disease models in order to understand whether or not ciliary signaling could 
contribute to disease progression and aging. 
6.5 PRELIMINARY RESULTS II 
MtDNA depletion is a particular condition observed in several pathological conditions such 
as cardiovascular disease, diabetes and cancer and might impair mitochondria and metabolic 
function of target tissues (49, 184). Mitochondrial and cellular metabolism is severely 
impaired when mtDNA is absent (e.g treatment with EtBr or Tfam knock out). Larsson and 
colleagues showed that homozygous knock out of Tfam is not compatible with life 
underlining that TFAM is necessary for development and survival (195). However, the 
mitochondrial metabolic alterations as a consequence of decreased mtDNA are not clear. In 
fact, in Tfam+/- mouse, where the TFAM and mtDNA levels are reduced to half, only a slight 
reduction of transcripts and single complex activities in the heart has been found, suggesting 
an excess of mitochondrial transcripts compared to cellular needs. In tissues such as the heart, 
the described phenotype might be related to a higher mtDNA turnover and abundance of 
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mitochondrial proteins. Corroborating the hypothesis of excess of transcripts, more than 60% 
reduction in TFAM and mtDNA in Drosophila affects only some mitochondrial transcripts 
turnover (mrRNA) (196). 
Our preliminary data suggest that mitochondrial bioenergetics is only partially dependent on 
the amount of mtDNA. In fact, we demonstrated that stably decreasing mtDNA copies up to 
60-80% in two metabolically different cell lines did not affect mitochondrial respiration. Our 
result is in line with a previous observation in cultured adipocytes (197). A possible 
explanation could be that there is a threshold for the amount of mtDNA under which the 
mitochondrial dysfunction leads to an impairment of cellular bioenergetics. It would be 
important in future research to understand the reason of the possible overabundance of 
mtDNA and the amount of mtDNA needed for different tissues to be metabolically healthy.  
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